

Objection Deadline: November 17, 2020 @ 12:00 p.m. (ET)

**UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK**

| | |
|--|-------------------------|
| In re: | Chapter 11 |
| PURDUE PHARMA L.P., <i>et al.</i> , ¹ | Case No. 19-23649 (RDD) |
| Debtors. | (Jointly Administered) |

**THIRTEENTH MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP,
FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS FOR
ALLOWANCE OF COMPENSATION FOR SERVICES
RENDERED AND FOR REIMBURSEMENT OF EXPENSES
FOR THE PERIOD OF SEPTEMBER 1, 2020 THROUGH SEPTEMBER 30, 2020**

| | | |
|--|--|--------------------|
| Name of Applicant: | ALIXPARTNERS, LLP | |
| Applicant’s Role in Case: | Financial Advisor to the Chapter 11 Debtors | |
| Date Order of Employment Signed: | November 21, 2019 [Docket No. 528], <i>Nunc Pro Tunc</i> to September 15, 2019 | |
| Time period covered by this statement: | Beginning of Period | End of Period |
| | September 1, 2020 | September 30, 2020 |
| Summary of Total Fees and Expenses Requested: | | |
| Total fees requested in this statement: | \$699,536.40 (80% of \$874,420.50) | |
| Total expenses requested in this statement: | \$0.00 | |
| Total fees and expenses requested in this statement: | \$699,536.40 | |
| This is a(n): <u> X </u> Monthly Application <u> </u> Interim Application <u> </u> Final Application | | |

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY PROFESSIONAL
FOR THE PERIOD SEPTEMBER 1, 2020 THROUGH SEPTEMBER 30, 2020**

| PROFESSIONAL | TITLE | RATE | HOURS | FEES |
|--|-----------------------|-------------|----------------|----------------------|
| Lisa Donahue | Managing Director | \$1,195 | 14.9 | \$ 17,805.50 |
| Richard Collura | Managing Director | \$1,090 | 33.0 | 35,970.00 |
| Jesse DelConte | Director | \$950 | 185.0 | 175,750.00 |
| Kevin M McCafferty | Director | \$950 | 198.5 | 188,575.00 |
| Mark F Rule | Director | \$910 | 2.7 | 2,457.00 |
| Gabe J Koch | Director | \$840 | 121.4 | 101,976.00 |
| HS Bhattal | Director | \$840 | 47.0 | 39,480.00 |
| Elizabeth S Kardos | Director | \$710 | 0.3 | 213.00 |
| Ryan D Sublett | Senior Vice President | \$735 | 1.2 | 882.00 |
| Isabel Arana de Uriate | Senior Vice President | \$690 | 2.5 | 1,725.00 |
| Sam J Canniff | Senior Vice President | \$645 | 86.2 | 55,599.00 |
| Kristina Galbraith | Senior Vice President | \$645 | 7.2 | 4,644.00 |
| Fernando O Silva | Senior Vice President | \$645 | 13.5 | 8,707.50 |
| Andrew D DePalma | Vice President | \$515 | 178.5 | 91,927.50 |
| Lan T Nguyen | Vice President | \$515 | 1.8 | 927.00 |
| Sam K Lemack | Vice President | \$515 | 156.1 | 80,391.50 |
| Nate A Simon | Vice President | \$515 | 102.5 | 52,787.50 |
| Tammy Brewer | Vice President | \$450 | 3.2 | 1,440.00 |
| Melanie McCabe | Vice President | \$415 | 30.2 | 12,533.00 |
| Roy Ellis Ochoa | Consultant | \$420 | 1.5 | 630.00 |
| Total Professional Hours and Fees | | | 1,187.2 | \$ 874,420.50 |
| Less 50% Travel Fees | | | | - |
| Subtotal | | | | \$ 874,420.50 |
| Less 20% Holdback | | | | (174,884.10) |
| Invoice Total | | | | \$ 699,536.40 |
| Average Billing Rate | | | | \$ 736.54 |

ALIXPARTNERS, LLP

SUMMARY OF HOURS AND FEES BY MATTER CATEGORY
FOR THE PERIOD SEPTEMBER 1, 2020 THROUGH SEPTEMBER 30, 2020

| CODE | MATTER CATEGORY | HOURS | FEES |
|-------------|---|-----------------------------|----------------------|
| 101 | Chapter 11 Process/Case Management | 50.7 | \$ 43,600.50 |
| 103 | Cash Management | 141.2 | 82,142.00 |
| 104 | Communication with Interested Parties | 43.5 | 32,494.00 |
| 105 | U.S. Trustee / Court Reporting Requirements | 7.1 | 3,961.00 |
| 106 | Business Analysis & Operations | 623.3 | 503,804.50 |
| 107 | POR Development | 61.6 | 39,585.50 |
| 109 | Claims Process | 1.1 | 566.50 |
| 110 | Special Projects | 66.5 | 35,183.50 |
| 112 | Retention and Engagement Administration | 0.3 | 213.00 |
| 113 | Fee Statements and Fee Applications | 40.6 | 20,813.00 |
| 114 | Court Hearings | 9.2 | 7,063.00 |
| 115 | Forensic Analysis | 142.1 | 104,994.00 |
| | | 1,187.2 | \$ 874,420.50 |
| | | | |
| | | Average Billing Rate | \$ 736.54 |

AlixPartners, LLP (“AlixPartners”), as financial advisor to the Debtors and its affiliated Debtors, (collectively, the “Debtors”), hereby submits this Thirteenth Monthly Fee Statement seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period September 1, 2020 through September 30, 2020 (the “Compensation Period”), pursuant to the *Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals* [Docket No. 528] and the *Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019* [Docket No. 528].

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

[Remainder of page intentionally left blank.]

WHEREFORE, AlixPartners respectfully requests that it be granted an allowance of compensation for professional services rendered during the Compensation Period in the amount of \$874,420.50, without prejudice to a final allowance of compensation, and that the Court grant AlixPartners such other and further relief as is just and proper. Pursuant to the Interim Compensation Order, AlixPartners seeks payment of professional fees in the amount of \$699,536.50 (80% of \$874,420.50), for a total amount of \$699,536.50.

Dated: November 3, 2020

ALIXPARTNERS, LLP
909 Third Avenue, 28th Floor
New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue
Managing Director

Exhibit A

AlixPartners, LLP

Detailed Description of AlixPartners' Fees and Hours by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/01/20 | LJD | Update call with L. Donahue, J. DelConte, G. Koch, (all AlixPartners), M.Huebner, J.McClammy, E.Vonnegut, B.Kaminetzky, T.Graulich, C.Robertson (all Davis Polk), J.O'Connell, T.Coleman, J.Turner (all PJT Partners). | 0.60 |
| 09/01/20 | GJK | Update call with L. Donahue, J. DelConte, G. Koch, (all AlixPartners), M. Huebner, J. McClammy, E. Vonnegut, B. Kaminetzky, T. Graulich, C. Robertson (all Davis Polk), J. O'Connell, T. Coleman, J. Turner (all PJT Partners). | 0.60 |
| 09/01/20 | JD | Prepare for and attend update call with L. Donahue, J. DelConte, G. Koch, (all AlixPartners), M. Huebner, J. McClammy, E. Vonnegut, B. Kaminetzky, T. Graulich, C. Robertson (all Davis Polk), J. O'Connell, T. Coleman, J. Turner (all PJT Partners). | 1.00 |
| 09/01/20 | HSB | Update call with L. Donahue, J. DelConte, G. Koch, (all AlixPartners), M.Huebner, J.McClammy, E.Vonnegut, B.Kaminetzky, T.Graulich, C.Robertson (all Davis Polk), J.O'Connell, T.Coleman, J.Turner (all PJT Partners). | 0.60 |
| 09/02/20 | JD | Prepare agenda for meeting tomorrow with management, AlixPartners, PJT and Davis Polk. | 0.40 |
| 09/03/20 | JD | Call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (both Davis Polk), T. Coleman, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: weekly catch up call with management and advisors. | 1.10 |
| 09/03/20 | HSB | Call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (both Davis Polk), T. Coleman, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: weekly catch up call with management and advisors. | 1.10 |
| 09/03/20 | LJD | Call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (both Davis Polk), | 1.10 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | T. Coleman, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: weekly catch up call with management and advisors. | |
| 09/04/20 | MFR | Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update. | 0.50 |
| 09/04/20 | SJC | Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update. | 0.50 |
| 09/04/20 | GJK | Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update. | 0.50 |
| 09/04/20 | HSB | Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update. | 0.50 |
| 09/04/20 | JD | Prepare agenda for AlixPartners weekly update call. | 0.30 |
| 09/04/20 | JD | Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update. | 0.50 |
| 09/04/20 | KM | Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update. | 0.50 |
| 09/08/20 | HSB | Call with M. Huebner, C. Robertson, B. Kamenetsky (Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and planning go-forward. | 0.60 |
| 09/08/20 | GJK | Call with M. Huebner, C. Robertson, B. Kamenetsky (Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and planning go-forward. | 0.60 |
| 09/08/20 | JD | Compose agenda for weekly professionals call. | 0.30 |
| 09/08/20 | JD | Call with M. Huebner, C. Robertson, B. Kamenetsky (Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and planning go-forward. | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/08/20 | LJD | Call with M. Huebner, C. Robertson, B. Kamenetsky (Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and planning go-forward. | 0.60 |
| 09/09/20 | JD | Review draft agenda for tomorrow's call with the company and the professionals. | 0.20 |
| 09/10/20 | JD | Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte and G. Koch (all AlixPartners) re: weekly update. | 0.50 |
| 09/10/20 | JD | Review final wages motion and declarations. | 1.50 |
| 09/10/20 | JD | Call with J. Lowne (Purdue) re: post-call catch up. | 0.20 |
| 09/10/20 | GJK | Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte and G. Koch (all AlixPartners) re: weekly update. | 0.50 |
| 09/10/20 | LJD | Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte and G. Koch (all AlixPartners) re: weekly update. | 0.50 |
| 09/11/20 | LJD | Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update: | 0.40 |
| 09/11/20 | MFR | Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update: | 0.40 |
| 09/11/20 | FOS | Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. | 0.40 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update: | |
| 09/11/20 | SKL | Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update: | 0.40 |
| 09/11/20 | NAS | Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update: | 0.40 |
| 09/11/20 | GJK | Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update: | 0.40 |
| 09/11/20 | JD | Prepare agenda for weekly AlixPartners call. | 0.40 |
| 09/11/20 | JD | Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update: | 0.40 |
| 09/11/20 | HSB | Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update: | 0.40 |
| 09/16/20 | JD | Create agenda for all hands call tomorrow morning. | 0.40 |
| 09/17/20 | JD | Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning. | 0.80 |
| 09/17/20 | GJK | Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning. | 0.80 |
| 09/17/20 | LJD | Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all | 0.80 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning. | |
| 09/17/20 | HSB | Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning. | 0.80 |
| 09/18/20 | ADD | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.60 |
| 09/18/20 | ADD | Prepare for Purdue internal team update call. | 0.50 |
| 09/18/20 | KM | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.60 |
| 09/18/20 | FOS | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.60 |
| 09/18/20 | MFR | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.60 |
| 09/18/20 | SKL | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.60 |
| 09/18/20 | SJC | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.60 |
| 09/18/20 | NAS | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | Simon (all AlixPartners) re: Weekly update. | |
| 09/18/20 | JD | Prepare agenda for weekly AlixPartners call. | 0.30 |
| 09/18/20 | JD | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.60 |
| 09/18/20 | GJK | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.60 |
| 09/21/20 | HSB | Review PBGC claims related issues and requested information from Fidelity. | 1.10 |
| 09/22/20 | HSB | Call with M. Huebner, B. Kamenetsky, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly advisors catch up call. | 0.60 |
| 09/22/20 | JD | Call with M. Huebner, B. Kamenetsky, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly advisors catch up call. | 0.60 |
| 09/22/20 | GJK | Call with M. Huebner, B. Kamenetsky, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly advisors catch up call. | 0.60 |
| 09/22/20 | LJD | Call with M. Huebner, B. Kamenetsky, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly advisors catch up call. | 0.60 |
| 09/24/20 | LJD | Prepare for and attend weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (both AlixPartners), M. Huebner, C. Robertson (all Davis Polk), J. O'Connell, T. Melvin (both | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | PJT) re: go forward planning. | |
| 09/24/20 | GJK | Prepare for and attend weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (both AlixPartners), M. Huebner, C. Robertson (all Davis Polk), J. O'Connell, T. Melvin (both PJT) re: go forward planning. | 0.60 |
| 09/24/20 | JD | Weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (both AlixPartners), M. Huebner, C. Robertson (all Davis Polk), J. O'Connell, T. Melvin (both PJT) re: go forward planning. | 0.50 |
| 09/24/20 | HSB | Review C. Landau (Purdue) UCC presentation dated July 2020. | 1.10 |
| 09/24/20 | HSB | Review C. Landau (Purdue) UCC presentation dated Feb 2020 ahead of meeting re: C. Landau (Purdue) deposition. | 0.90 |
| 09/25/20 | HSB | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.70 |
| 09/25/20 | LTN | Intro to case call with L. Nguyen and J. DelConte (both AlixPartners). | 0.60 |
| 09/25/20 | ADD | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.70 |
| 09/25/20 | ADD | Prepare for Purdue AlixPartners engagement team update call. | 0.40 |
| 09/25/20 | JD | Prepare agenda for weekly AlixPartners call. | 0.30 |
| 09/25/20 | JD | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.70 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/25/20 | JD | Intro to case call with L. Nguyen and J. DelConte (both AlixPartners). | 0.60 |
| 09/25/20 | GJK | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.70 |
| 09/25/20 | FOS | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.70 |
| 09/25/20 | SKL | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.70 |
| 09/25/20 | NAS | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.70 |
| 09/25/20 | SJC | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.70 |
| 09/28/20 | JD | Correspondence with A. DePalma and S. Lemack (both AlixPartners) re: workplan and staffing. | 0.40 |
| 09/28/20 | HSB | Conduct online research related to request from Davis Polk. | 0.40 |
| 09/29/20 | HSB | Review KERP motion prepared by Davis Polk. | 0.80 |
| 09/29/20 | HSB | Review PBGC claim and prepare response to latest inquiry re: PBGC claim calculation. | 0.80 |
| 09/29/20 | HSB | Call with M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch and H. Bhattal (all AlixPartners) re: weekly professionals planning call. | 0.30 |
| 09/29/20 | JD | Call with M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. | 0.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

| Date | Consultant | Description of Services | Hours |
|--------------|------------|--|--------------|
| | | DelConte, G. Koch and H. Bhattal (all AlixPartners) re: weekly professionals planning call. | |
| 09/29/20 | NAS | Review motions related to extension of preliminary injunction posted to docket. | 0.70 |
| 09/29/20 | GJK | Call with M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch and H. Bhattal (all AlixPartners) re: weekly professionals planning call. | 0.30 |
| 09/29/20 | LJD | Call with M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch and H. Bhattal (all AlixPartners) re: weekly professionals planning call. | 0.30 |
| 09/30/20 | LJD | Call with L. Donahue and J. DelConte (both AlixPartners) re: workplan and go forward staffing needs. | 0.40 |
| 09/30/20 | JD | Review motions filed by the UCC re: discovery and privileged documents. | 1.10 |
| 09/30/20 | JD | Call with L. Donahue and J. DelConte (both AlixPartners) re: workplan and go forward staffing needs. | 0.40 |
| 09/30/20 | JD | Prepare agenda for tomorrow's call with all of the professionals and management. | 0.30 |
| 09/30/20 | HSB | Review recently court filings re: OCP cap raise and new addition. | 0.20 |
| Total | | | 50.70 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|--------------|----------|------------------|
| Andrew D DePalma | 2.20 | 515.00 | 1,133.00 |
| Sam K Lemack | 1.70 | 515.00 | 875.50 |
| Lan T Nguyen | 0.60 | 515.00 | 309.00 |
| Nate A Simon | 2.40 | 515.00 | 1,236.00 |
| Fernando O Silva | 1.70 | 645.00 | 1,096.50 |
| Sam J Canniff | 1.80 | 645.00 | 1,161.00 |
| Gabe J Koch | 6.20 | 840.00 | 5,208.00 |
| HS Bhattal | 10.90 | 840.00 | 9,156.00 |
| Mark F Rule | 1.50 | 910.00 | 1,365.00 |
| Kevin M McCafferty | 1.10 | 950.00 | 1,045.00 |
| Jesse DelConte | 14.70 | 950.00 | 13,965.00 |
| Lisa Donahue | 5.90 | 1,195.00 | 7,050.50 |
| Total Hours & Fees | 50.70 | | 43,600.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Cash Management
Client/Matter # 012589.00103

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/01/20 | JD | Review draft of settlement cash flow forecast from PJT. Provide comments re: same. | 0.40 |
| 09/01/20 | SKL | Create accounts payable release files. | 0.60 |
| 09/01/20 | SKL | Prepare and finalize updates to the operating expense section of the latest 13-week cash forecast. | 2.10 |
| 09/01/20 | SKL | Review the latest Purdue rebate tracker and updated the customer rebate section of the Purdue cash forecast accordingly. | 2.10 |
| 09/01/20 | SKL | Prepare and finalize updates to the customer receipt section of the Purdue cash forecast. | 1.90 |
| 09/01/20 | SKL | Review the latest updates to the IAC disbursement section of the Purdue cash forecast and finalize accordingly. | 1.10 |
| 09/01/20 | SKL | Review the latest updates to the IAC receipt section of the Purdue cash forecast and finalize accordingly. | 1.40 |
| 09/02/20 | SKL | Prepare and finalize updates to the operating expense section of the latest Rhodes cash forecast. | 2.20 |
| 09/02/20 | SKL | Prepare and finalize updates to the customer receipt section of the latest Rhodes cash forecast. | 2.00 |
| 09/02/20 | SKL | Review and finalize updates to the customer rebate section of the latest Rhodes cash forecast. | 1.70 |
| 09/02/20 | SKL | Create accounts payable release files. | 0.70 |
| 09/02/20 | SKL | Finalize remaining updates to the Purdue and Rhodes forecast deck and circulate internally for review and sign- off. | 2.30 |
| 09/03/20 | SKL | Create accounts payable release files. | 0.70 |
| 09/03/20 | SKL | Review and prepare update on the restructuring invoice inquiry per C. MacDonald (Purdue) request. | 0.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Cash Management
Client/Matter # 012589.00103

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/03/20 | JD | Review and provide comments on the latest cash forecast file. | 0.70 |
| 09/03/20 | JD | Review comments from Davis Polk on the settlement cash forecast analysis from PJT. | 0.40 |
| 09/03/20 | HSB | Review 13-week cash forecast (for period beginning with week ended 8/28) prepared by S. Lemack (AlixPartners). | 0.80 |
| 09/04/20 | JD | Review latest version of the cash settlement forecast. | 0.30 |
| 09/04/20 | SKL | Review latest restructuring fee approvals and updated invoices for today's AP release file. | 1.50 |
| 09/07/20 | JD | Correspondence with S. Lemack (AlixPartners) re: cash forecast and KEIP/KERP amounts. | 0.30 |
| 09/08/20 | SKL | Review latest KEIP/KERP motion and updated the cash forecast accordingly. | 1.50 |
| 09/08/20 | SKL | Review the latest Paysource transaction report and updated the week ended 08/28 cash report accordingly. | 2.00 |
| 09/08/20 | SKL | Finalize review of the week ended 08/28 EastWest cash report and updated categorizations accordingly. | 2.10 |
| 09/08/20 | SKL | Finalize updates to the Purdue and Rhodes IAC summaries re: week ended 08/28 weekly cash report. | 1.90 |
| 09/08/20 | SKL | Create accounts payable release file. | 0.60 |
| 09/08/20 | SKL | Finalize updates to the Purdue forecast-to-actuals analysis re: week ended 08/28 cash report. | 0.60 |
| 09/08/20 | SKL | Finalize updates to the Rhodes forecast-to-actuals analysis re: week ended 08/28 cash report. | 0.40 |
| 09/08/20 | JD | Review latest draft cash flow forecast. | 0.60 |
| 09/09/20 | JD | Review latest draft illustrative settlement cash flow forecast. | 0.40 |
| 09/09/20 | JD | Review final cash forecast prior to sending to the | 0.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Cash Management
Client/Matter # 012589.00103

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | company. | |
| 09/09/20 | JD | Review updated cash forecast per management comments. | 0.30 |
| 09/09/20 | JD | Review latest cash forecast to actual reporting. | 0.40 |
| 09/09/20 | SKL | Review of week ended 09/04 EastWest transactions report and categorizing transactions. | 2.00 |
| 09/09/20 | SKL | Pull latest Paysource transaction report and began matching to the latest EastWest report accordingly. | 1.90 |
| 09/09/20 | SKL | Finalize updates to the IAC and investment summaries re: week ended 09/04 weekly cash report and prepare list of open items for E. Nowakowski (Purdue) accordingly. | 2.10 |
| 09/09/20 | SKL | Create accounts payable release file. | 0.70 |
| 09/09/20 | HSB | Review weekly cash report (for week ended 8/28) prepared by S. Lemack (AlixPartners). | 0.70 |
| 09/10/20 | RDS | Review API plant unit economics and resulting cash flow bridge | 0.70 |
| 09/10/20 | SKL | Create accounts payable release file. | 0.90 |
| 09/11/20 | SKL | Prepare updated Purdue forecast-to-actuals analysis re: week ended 09/04 cash report. | 0.90 |
| 09/11/20 | SKL | Prepare updated Rhodes forecast-to-actuals analysis re: week ended 09/04 cash report. | 0.80 |
| 09/14/20 | SKL | Create accounts payable release file. | 0.70 |
| 09/14/20 | SKL | Finalize forecast-to-actuals and prepare and circulate week ended 09/04 cash report. | 2.40 |
| 09/14/20 | SKL | Review and prepare update to the latest critical vendor inquiry provided by R. Haberlin (Purdue). | 0.60 |
| 09/14/20 | JD | Review last week's forecast to actual analysis. | 0.30 |
| 09/14/20 | GJK | Review Mundipharma new statement of cash flows. | 2.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Cash Management
Client/Matter # 012589.00103

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/14/20 | HSB | Review weekly cash report (week ended 9/041) prepared by S. Lemack (AlixPartners). | 0.90 |
| 09/15/20 | GJK | Review Mundipharma updated balance sheet and cash forecast. | 3.00 |
| 09/15/20 | SKL | Review the latest EastWest transactions report and began categorizing transactions for the week ended 09/11 weekly cash report. | 2.20 |
| 09/15/20 | SKL | Prepare the cash activity, disbursements and credits, section of the August monthly operating report and circulate internally. | 2.10 |
| 09/15/20 | SKL | Review the latest bank account activity for the month of August and prepare and circulate the August bank balances for the August monthly operating report. | 1.80 |
| 09/15/20 | SKL | Create accounts payable release file. | 0.70 |
| 09/16/20 | SKL | Create accounts payable release file. | 0.70 |
| 09/16/20 | SKL | Review the latest Paysource transactions report and incorporate into the latest weekly cash report. | 1.70 |
| 09/16/20 | SKL | Review the latest professional payment information and prepare and circulate the latest professional payment piece of the August Monthly Operating Report. | 2.40 |
| 09/16/20 | SKL | Review the latest feedback provided by C. MacDonald (Purdue) and circulate updated report accordingly. | 0.50 |
| 09/16/20 | SKL | Review the latest IAC cash activity and prepare and circulate list of open cash items for T. Gabriele (Purdue) and R. Brown (Purdue). | 1.90 |
| 09/16/20 | NAS | Build projections of Mundipharma free cash flow by product category. | 1.00 |
| 09/17/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to review initial analysis of Mundipharma free cash flow by product | 0.40 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Cash Management
Client/Matter # 012589.00103

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | category. | |
| 09/17/20 | NAS | Finalize analysis of Mundipharma free cash flow by product category across scenarios. | 2.70 |
| 09/17/20 | NAS | Analyze movements in Mundipharma product category free cash flow relative to prior iteration of model. | 1.30 |
| 09/17/20 | SKL | Create accounts payable release file. | 0.90 |
| 09/17/20 | SKL | Reviewed latest cash transaction feedback provided by S. Visciglia (Purdue) and R. Brown (Purdue) and updated the week ended 09/11 cash report accordingly. | 1.60 |
| 09/17/20 | SKL | Update the restructuring professional fee tracker with the latest fee applications files. | 1.10 |
| 09/17/20 | SKL | Review and reconcile latest critical vendor payment inquiry provided by M. Kroese (Purdue) and prepare update accordingly. | 0.70 |
| 09/17/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to review initial analysis of Mundipharma free cash flow by product category. | 0.40 |
| 09/17/20 | HSB | Review July Flash report (PEO version) prepared by S. Lemack (AlixPartners) and provide feedback. | 1.90 |
| 09/18/20 | HSB | Review July 2020 full board presentation. | 2.40 |
| 09/18/20 | HSB | Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update. | 0.50 |
| 09/18/20 | HSB | Review weekly cash report (week ended 9/11) prepared by S. Lemack (AlixPartners). | 1.20 |
| 09/18/20 | JD | Review and provide comments on latest forecast to actual cash reporting. | 0.60 |
| 09/18/20 | SKL | Create accounts payable release file. | 0.70 |
| 09/18/20 | SKL | Finalize updates to the Purdue forecast-to-actuals and | 1.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Cash Management
Client/Matter # 012589.00103

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | update the weekly cash report accordingly. | |
| 09/18/20 | SKL | Finalize updates to the Rhodes forecast-to-actuals and update the weekly cash report accordingly. | 1.20 |
| 09/18/20 | SKL | Finalize review of July board presentation and circulate final July Flash report for review | 2.30 |
| 09/21/20 | SKL | Create accounts payable release file. | 0.70 |
| 09/21/20 | SKL | Finalize updates to the weekly cash report and circulate to J. Lowne (Purdue) for final sign-off. | 1.80 |
| 09/21/20 | NAS | Provide detailed Mundipharma free cash flow projections by product category to PJT. | 0.90 |
| 09/21/20 | JD | Review latest cash forecast to actual report and give final comments. | 0.40 |
| 09/22/20 | JD | Review latest version of the settlement cash flows to be sent to the Board. | 0.30 |
| 09/22/20 | SKL | Review and reconcile the latest East West cash transactions report and began categorizing for the latest weekly cash report. | 2.20 |
| 09/22/20 | SKL | Review and reconcile the latest Paysource transactions report and began categorizing for the latest weekly cash report. | 2.00 |
| 09/22/20 | SKL | Create accounts payable release files. | 0.70 |
| 09/22/20 | HSB | Review weekly sales product reports for Purdue and Rhodes prepared by S. Lemack (AlixPartners) | 0.30 |
| 09/23/20 | SKL | Create accounts payable release files. | 0.70 |
| 09/23/20 | SKL | Prepare the latest IAC cash summaries and circulate list of open items to S. Visciglia (Purdue). | 1.50 |
| 09/23/20 | SKL | Review and reconcile latest rebate activity and circulate list of open questions to C. Hobbick (Purdue). | 0.70 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Cash Management
Client/Matter # 012589.00103

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/23/20 | SKL | Review latest critical vendor payment inquiry and next steps. | 0.40 |
| 09/23/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) and J. Arsic (PJT) to review Mundipharma free cash flow by product category analysis. | 0.40 |
| 09/23/20 | JD | Review and comment on the draft email to the Board re: illustrative cash settlement forecast. | 0.30 |
| 09/23/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) and J. Arsic (PJT) to review Mundipharma free cash flow by product category analysis. | 0.40 |
| 09/24/20 | SKL | Update the Purdue forecast with the latest format changes made to the Purdue cash actuals and prepare the latest Purdue forecast-to-actuals. | 2.10 |
| 09/24/20 | LJD | Review board presentation on cash flows | 0.60 |
| 09/24/20 | SKL | Create accounts payable release files. | 0.70 |
| 09/24/20 | SKL | Finalize updates to the Rhodes section of the weekly cash report and updated the formatting to match the latest Rhodes forecast. | 1.80 |
| 09/24/20 | SKL | Finalize updates to the Purdue section of the weekly cash report and updated the formatting to match the latest Purdue forecast. | 2.10 |
| 09/25/20 | SKL | Create accounts payable release files. | 0.70 |
| 09/25/20 | SKL | Update the Rhodes forecast with the latest format changes made to the Purdue cash actuals and prepare the latest Rhodes forecast-to-actuals. | 1.30 |
| 09/25/20 | SKL | Continue review of the latest critical vendor inquiry provided by R. Haberlin (Purdue) and prepare updated breakdown accordingly. | 0.80 |
| 09/27/20 | HSB | Review July 2020 full board presentation and C. Landau | 1.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Cash Management
Client/Matter # 012589.00103

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | (Purdue) presentation in response to request for info for KERP related data. | |
| 09/27/20 | HSB | Compile summary of Purdue operating performance statistics, management initiatives & qualitative data in response to request for info for KERP related data. | 0.80 |
| 09/28/20 | HSB | Review weekly cash report (week ended 9/18) prepared by S. Lemack (AlixPartners). | 0.90 |
| 09/28/20 | SKL | Finalize remaining updates to the week ended 09.18 weekly cash report and circulate for final sign-off. | 2.10 |
| 09/28/20 | SKL | Create accounts payable release file. | 0.90 |
| 09/28/20 | SKL | Finalize updates to the format of the Purdue cash detail in the 09.18 weekly cash report and circulate for sign-off. | 1.20 |
| 09/28/20 | JD | Review and provide comments on last week's forecast to actual cash report. | 0.50 |
| 09/29/20 | SKL | Review latest OCP fee/expense detail provided by C. MacDonald (Purdue) and prepare updated OCP report accordingly. | 1.90 |
| 09/29/20 | SKL | Review and reconcile latest East West cash transactions report and began categorizing for the week ended 09.25 cash report accordingly. | 2.10 |
| 09/29/20 | SKL | Review and reconcile latest critical vendor inquiry and prepare list of open items and updates accordingly. | 0.60 |
| 09/29/20 | SKL | Review latest A/R activity and prepare open item inquiry for E. Nowakowski (Purdue) and team to provide update re: A/R aging. | 0.50 |
| 09/29/20 | SKL | Create accounts payable release file. | 0.70 |
| 09/30/20 | SKL | Create accounts payable release file. | 0.60 |
| 09/30/20 | SKL | Meeting with A. DePalma, L. Nguyen, S. Lemack (all AlixPartners) re: weekly cash reporting processes and | 1.20 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Cash Management
Client/Matter # 012589.00103

| Date | Consultant | Description of Services | Hours |
|--------------|------------|--|---------------|
| | | procedures. | |
| 09/30/20 | SKL | Review and reconcile latest Paysource transactions report and began categorizing and implemented into the week ended 09.25 cash report accordingly. | 1.80 |
| 09/30/20 | SKL | Finalize updates to the August OCP report based on the feedback provided by C. MacDonald (Purdue) and circulate to the Davis Polk team for sign-off and to submit. | 1.40 |
| 09/30/20 | SKL | Update the no-hold vendor list based on the updates provided by C. MacDonald (Purdue). | 0.40 |
| 09/30/20 | SKL | Prepare for and participate in discussion with C. MacDonald (Purdue) re: August OCP activity. | 0.50 |
| 09/30/20 | SKL | Finalize review of latest cash transactions and circulate list of open items to T. Gabriele, E. Nowakowski, C. Hobbick and S. Visciglia (all Purdue) to provide updates. | 1.70 |
| 09/30/20 | SKL | Review latest investment related activity and update to Purdue cash summary and Purdue cash detailed summary accordingly. | 1.30 |
| 09/30/20 | HSB | Review monthly OCP report prepared by S. Lemack and provide comments. | 0.30 |
| 09/30/20 | LTN | Meeting with A. DePalma, L. Nguyen, S. Lemack (all AlixPartners) re: weekly cash reporting processes and procedures. | 1.20 |
| 09/30/20 | ADD | Meeting with A. DePalma, L. Nguyen, S. Lemack (all AlixPartners) re: weekly cash reporting processes and procedures. | 1.20 |
| Total | | | 141.20 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|---------------|----------|------------------|
| Andrew D DePalma | 1.20 | 515.00 | 618.00 |
| Sam K Lemack | 105.80 | 515.00 | 54,487.00 |
| Lan T Nguyen | 1.20 | 515.00 | 618.00 |
| Nate A Simon | 6.70 | 515.00 | 3,450.50 |
| Ryan D Sublett | 0.70 | 735.00 | 514.50 |
| Gabe J Koch | 6.30 | 840.00 | 5,292.00 |
| HS Bhattal | 12.00 | 840.00 | 10,080.00 |
| Jesse DelConte | 6.70 | 950.00 | 6,365.00 |
| Lisa Donahue | 0.60 | 1,195.00 | 717.00 |
| Total Hours & Fees | 141.20 | | 82,142.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Communication with Interested Parties
Client/Matter # 012589.00104

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/02/20 | JD | Correspondence with Province and Akin Gump re: responses to open UCC diligence questions on the KEIP/KERP motion. | 0.40 |
| 09/02/20 | JD | Review questions from M. Atkinson (Province) re: KEIP/KERP diligence information. Prepare response re: same. | 1.50 |
| 09/03/20 | JD | Correspondence with Davis Polk and Willis Towers Watson re: questions from Akin Gump on the KEIP/KERP. | 0.70 |
| 09/03/20 | JD | Review responses to AHC diligence requests. | 0.30 |
| 09/04/20 | JD | Correspondence with M. Atkinson (Province) re: KEIP/KERP diligence questions. | 0.70 |
| 09/05/20 | ADD | Prepare and upload documents processed by Davis Polk's eDiscovery team for upload to the data room. | 2.80 |
| 09/08/20 | JD | Call with B. Bromberg, C. Kim (both FTI) re: KEIP/KERP. | 0.70 |
| 09/08/20 | JD | Review open KEIP/KERP questions from the AHC prior to our call. | 0.50 |
| 09/08/20 | JD | Draft responses to additional questions from FTI re: KEIP/KERP calculations and comparisons. | 1.10 |
| 09/08/20 | JD | Draft and send correspondence to FTI with preliminary KEIP/KERP diligence responses. | 0.50 |
| 09/10/20 | JD | Prepare responses to requests from FTI re: KEIP / KERP and correspondence re: same. | 1.20 |
| 09/10/20 | JD | Finalize schedule of Prime Clerk invoices to provide to creditor advisors. | 0.40 |
| 09/12/20 | JD | Correspondence with Purdue and Davis Polk re: AG settlement contracts. | 0.30 |
| 09/14/20 | JD | Review diligence question responses to AHC business plan questions. | 0.40 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Communication with Interested Parties
Client/Matter # 012589.00104

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/14/20 | JD | Correspondence with Purdue re: HRT follow up questions from the UCC. | 0.70 |
| 09/14/20 | JD | Correspondence with Davis Polk and Purdue re: UCC questions on AG settlements and Project Catalyst. | 0.50 |
| 09/15/20 | JD | Prepare responses to Province re: Project Catalyst, HRT and KEIP/KERP. Correspondence with Purdue, Davis Polk and Willis Tower Watson re: same. | 2.60 |
| 09/15/20 | JD | Prepare draft set of responses to AHC diligence questions on the KEIP/KERP. | 0.70 |
| 09/16/20 | JD | Correspondence with C. DeStefano (Purdue) re: bonus clawbacks from employee resignations. | 0.30 |
| 09/16/20 | JD | Meeting with B. Bromberg, C. Kim (both FTI) re: KEIP/KERP analysis. | 0.60 |
| 09/16/20 | JD | Finalize analysis and draft final responses to FTI re: open KEIP/KERP diligence questions. | 2.10 |
| 09/16/20 | ADD | Upload files provided by Davis Polk's eDiscovery team to the data room for creditor committee review. | 1.30 |
| 09/17/20 | ADD | Draft correspondences to request materials responsive to committee diligence requests. | 0.40 |
| 09/18/20 | JD | Call with M. Atkinson (Province) re: KEIP/KERP response. | 0.20 |
| 09/18/20 | JD | Correspondence with Purdue and Davis Polk re: AHC request to share certain KEIP/KERP information. | 0.50 |
| 09/18/20 | JD | Correspondence with Purdue re: diligence request from Province on AG settlements. | 0.70 |
| 09/21/20 | JD | Call with M. Kesselman (Purdue), M. Huebner and E. Vonnegut (both Davis Polk) re: KEIP/KERP responses. | 0.40 |
| 09/21/20 | JD | Call with M. Kesselman (Purdue), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, R. Schnitzler, J. Turner (all PJT) re: communications with the non- | 1.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Communication with Interested Parties
Client/Matter # 012589.00104

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | consenting state group. | |
| 09/21/20 | JD | Follow up email with FTI re: outstanding diligence questions. | 0.30 |
| 09/21/20 | JD | Correspondence with Davis Polk re: FTI discussion with Bates White. | 0.20 |
| 09/21/20 | JD | Call with M. Huebner (Davis Polk), M. Kesselman (Purdue), J. O'Connell, J. Turner (both PJT) and third party re: business plans. | 0.80 |
| 09/21/20 | ADD | Prepare and upload documents provide by Davis Polk's eDiscovery team for upload to the data room. | 1.20 |
| 09/22/20 | ADD | Compile and prepare materials submitted in response to diligence requests for upload to the data room. | 2.00 |
| 09/22/20 | JD | Call with M. Diaz (FTI) re: KEIP/KERP. | 0.40 |
| 09/22/20 | JD | Correspondence with Davis Polk re: additional AHC requests. | 0.30 |
| 09/22/20 | JD | Review KEIP/KERP objections from the UST and another ad hoc committee. | 0.60 |
| 09/23/20 | ADD | Compile and prepare materials submitted in response to diligence requests for upload to the data room. | 1.60 |
| 09/23/20 | ADD | Prepare and upload documents provide by Davis Polk's eDiscovery team for upload to the data room. | 1.40 |
| 09/24/20 | ADD | Research inquiry from vendor re: outstanding prepetition balance. | 1.70 |
| 09/24/20 | ADD | Compile list of third-party entities for AlixPartners eDiscovery team to redact from board presentation materials. | 1.20 |
| 09/24/20 | ADD | Compile and prepare materials submitted in response to diligence requests for upload to the data room. | 2.20 |
| 09/25/20 | ADD | Compile and prepare materials submitted in response to | 1.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Communication with Interested Parties
Client/Matter # 012589.00104

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|--------------|
| | | diligence requests for upload to the data room. | |
| 09/28/20 | ADD | Review board material redactions in preparation for upload to the data room for creditor review. | 1.70 |
| 09/28/20 | JD | Correspondence with Davis Polk and management re: KEIP/KERP objection responses. | 0.40 |
| 09/29/20 | JD | Review final non-PEO business plan refresh file to share with management. | 0.70 |
| 09/29/20 | SKL | Meeting with H. Bhattal, S. Lemack (both AlixPartners) re: latest PBGC inquiry and updates. | 0.40 |
| 09/29/20 | HSB | Meeting with H. Bhattal, S. Lemack (both AlixPartners) re: latest PBGC inquiry and updates. | 0.40 |
| 09/30/20 | ADD | Upload files provided by Davis Polk's eDiscovery team to the data room for creditor committee review. | 0.70 |
| 09/30/20 | JD | Correspondence with PJT and Davis Polk re: AHC request to share information. | 0.20 |
| Total | | | 43.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|--------------|--------|------------------|
| Andrew D DePalma | 19.80 | 515.00 | 10,197.00 |
| Sam K Lemack | 0.40 | 515.00 | 206.00 |
| HS Bhattal | 0.40 | 840.00 | 336.00 |
| Jesse DelConte | 22.90 | 950.00 | 21,755.00 |
| Total Hours & Fees | 43.50 | | 32,494.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------------|
| 09/09/20 | NAS | Request insider payments information from Purdue for purposes of August 2020 Monthly Operating Report. | 0.60 |
| 09/10/20 | NAS | Coordinate with Purdue/TXP employees re: MOR insider payments data requests. | 0.20 |
| 09/15/20 | NAS | Analyze and consolidate all data received for insider payments section of August 2020 MOR. | 1.20 |
| 09/16/20 | NAS | Finalize insider payments section of August 2020 MOR and review for accuracy. | 0.60 |
| 09/17/20 | ADD | Compile and prepare August MOR for CFO review and signature. | 2.40 |
| 09/18/20 | JD | Review draft MOR prior to sending to the company for signature. | 0.40 |
| 09/21/20 | JD | Correspondence with Purdue and Davis Polk re: MOR updates. | 0.30 |
| 09/21/20 | ADD | Update MOR per review comments in preparation to send to Davis Polk for upload. | 1.40 |
| Total | | | 7.10 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|-------------|--------|-----------------|
| Andrew D DePalma | 3.80 | 515.00 | 1,957.00 |
| Nate A Simon | 2.60 | 515.00 | 1,339.00 |
| Jesse DelConte | 0.70 | 950.00 | 665.00 |
| Total Hours & Fees | 7.10 | | 3,961.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/01/20 | ADD | Call with E. Vonnegut, W. Taylor, A. Lele, C. Robertson (Davis Polk) R. Aleali, K. McCarthy, B. Miller (Purdue), T. Melvin (PJT), A. DePalma, J. DelConte (both AlixPartners) re: trust transfer process. | 1.20 |
| 09/01/20 | KM | Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting. | 0.20 |
| 09/01/20 | KM | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Catalyst document review. | 0.90 |
| 09/01/20 | KM | Update diligence requests re: project Catalyst. | 0.70 |
| 09/01/20 | JD | Review updated employee roster and resignation and terminations information. Prepare analysis to create historical employee rosters. | 1.80 |
| 09/01/20 | JD | Review and edit draft KEIP / KERP motion. | 0.80 |
| 09/01/20 | JD | Finalize initial draft Wage Summary analysis. Tie back historical AIP and LTRP information against source files. Review analysis for employees who have left the company. | 3.10 |
| 09/01/20 | JD | Prepare analysis of LTRP reductions to share with the various creditor advisors. | 2.20 |
| 09/01/20 | KM | Analysis re: supply agreements for project Catalyst. | 2.10 |
| 09/01/20 | KM | Analysis and document management re: environmental diligence for Catalyst. | 0.80 |
| 09/01/20 | KM | Analysis re: APA schedules for project Catalyst. | 2.50 |
| 09/01/20 | KM | Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract diligence status | 0.70 |
| 09/01/20 | KM | Analysis re: IT agreements and approvals for project | 1.70 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | Catalyst. | |
| 09/01/20 | KM | Call with R. Schnitzler (PJT) re: project Catalyst. | 0.40 |
| 09/01/20 | JD | Correspondence with PJT re: scheduling a call re: Catalyst. | 0.20 |
| 09/01/20 | ADD | Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting. | 0.20 |
| 09/01/20 | ADD | Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract diligence status. | 0.70 |
| 09/01/20 | JD | Review updated attrition calculations from J. Lowne (Purdue) | 0.30 |
| 09/01/20 | JD | Review status of LTS invoices and correspondence with R. Aleali (Purdue) re: same. | 0.50 |
| 09/01/20 | JD | Call with J. Lowne (Purdue) re: attrition rates. | 0.10 |
| 09/01/20 | JD | Call with J. Lowne, R. Aleali, C. DeStefano, K. Laurel (all Purdue), E. Vonnegut, D. Consla, S. Brecher (all Davis Polk), D. Sims, S. Hinden (both Willis Towers Watson) re: KEIP/KERP. | 0.50 |
| 09/01/20 | JD | Call with E. Vonnegut, W. Taylor, A. Lele, C. Robertson (Davis Polk) R. Aleali, K. McCarthy, B. Miller (Purdue), T. Melvin (PJT), A. DePalma, J. DelConte (both AlixPartners) re: trust transfer process. | 1.20 |
| 09/01/20 | NAS | Revise Mundipharma business plan risk adjustments to align with latest findings and updated forecasts. | 3.30 |
| 09/01/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) re: projected Selling & Promotion expense in Mundipharma Base Case. | 1.30 |
| 09/01/20 | GJK | Review Mundipharma model variances and adjustments. | 2.00 |
| 09/01/20 | GJK | Review Mundipharma diligence responses to support | 2.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | model adjustments. | |
| 09/01/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) re: proposed risk adjustments to Mundipharma Base Case. | 1.00 |
| 09/01/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) re: projected Selling & Promotion expense in Mundipharma Base Case. | 1.30 |
| 09/01/20 | NAS | Analyze region- and product-level drivers behind Marketing expense change across Mundipharma forecasts. | 1.30 |
| 09/01/20 | NAS | Review new diligence responses provided by Huron/Mundipharma. | 0.50 |
| 09/01/20 | NAS | Review revised Mundipharma business plan model for accuracy and completeness. | 1.00 |
| 09/01/20 | NAS | Build P&L variance analysis for Mundipharma Risk-Adjusted Base Cases. | 0.80 |
| 09/01/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) re: proposed risk adjustments to Mundipharma Base Case. | 1.00 |
| 09/02/20 | IA | Review KEIP/KERP analysis and payments by employee detailed file. | 1.40 |
| 09/02/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to review risk adjustments made to Mundipharma Base Case. | 1.00 |
| 09/02/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma business plan update materials to be provided to PJT | 0.30 |
| 09/02/20 | NAS | Review Mundipharma risk-adjusted case for accuracy and comprehensiveness. | 1.70 |
| 09/02/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to review risk adjustments made to Mundipharma Base Case. | 1.00 |
| 09/02/20 | NAS | Review new diligence documents provided by | 0.40 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | Huron/Mundipharma. | |
| 09/02/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma business plan update materials to be provided to PJT | 0.30 |
| 09/02/20 | NAS | Build annotated variances between Base and Risk-Adjusted Cases for first and second iteration of Mundipharma business plan model to share with PJT. | 1.80 |
| 09/02/20 | LJD | Update call with J. Dubel (Board Member) | 0.40 |
| 09/02/20 | GJK | Review and assess Mundipharma model comparisons. | 2.50 |
| 09/02/20 | GJK | Review S&P adjustments between Mundipharma models. | 2.00 |
| 09/02/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies IT agreements for assignment. | 0.40 |
| 09/02/20 | JD | Review updated termed employee files from D. Warren (Purdue). | 0.50 |
| 09/02/20 | JD | Review and update employee wage summary file for latest information from the company. | 1.70 |
| 09/02/20 | JD | Call with R. Schnitzler, J. Turner (both PJT) and third party re: go forward planning. | 0.80 |
| 09/02/20 | JD | Call with J. Turner and R. Schnitzler (both PJT) re: follow up to third party call. | 0.30 |
| 09/02/20 | JD | Correspondence with PJT, Province, FTI, Jefferies and Houlihan re: scheduling a Catalyst call | 0.60 |
| 09/02/20 | JD | Correspondence with C. MacDonald (Purdue) re: professional fee payments. | 0.20 |
| 09/02/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies post-petition supply agreements. | 1.80 |
| 09/02/20 | KM | Analysis and document management re: schedules for | 1.40 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | Catalyst. | |
| 09/02/20 | KM | Analysis re: material supply agreements and spend for project Catalyst. | 0.50 |
| 09/02/20 | KM | Manage and post materials agreements re: project catalyst. | 1.10 |
| 09/02/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies IT agreements for assignment. | 0.40 |
| 09/02/20 | KM | Continue analysis re: material supply agreements and spend for project Catalyst. | 0.40 |
| 09/02/20 | KM | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Catalyst document review. | 2.30 |
| 09/02/20 | KM | Call with D. Fogel (Purdue) re: material IT agreements transfer status for project Catalyst. | 0.40 |
| 09/02/20 | KM | Analysis re: material IT agreements transfer status for project Catalyst. | 0.60 |
| 09/02/20 | KM | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: APA review. | 1.50 |
| 09/02/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies post-petition supply agreements. | 1.80 |
| 09/03/20 | KM | Analyze and edit APA and MSA schedule re: Catalyst. | 1.90 |
| 09/03/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: RT/RP agreements. | 2.50 |
| 09/03/20 | KM | Updates and analysis re: project Catalyst APA and MSA supporting documents. | 2.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/03/20 | KM | Call with D. Fogel (Purdue) re: RT employee retention. | 0.30 |
| 09/03/20 | KM | Analysis and document creation re: Catalyst agreement schedules. | 1.90 |
| 09/03/20 | KM | Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: materials agreements and excluded contracts for schedules. | 0.20 |
| 09/03/20 | KM | Analysis re: RT/RP agreements. | 0.10 |
| 09/03/20 | KM | Advisors call with J. DelConte (AlixPartners), R. Schnitzler (PJT), Jeffries, FTI, HL re: project Catalyst. | 0.50 |
| 09/03/20 | KM | Analysis re: RT/RP agreements. | 0.40 |
| 09/03/20 | ADD | Compile SAP data and update liabilities subject to compromise report for August. | 1.10 |
| 09/03/20 | ADD | Call J. DelConte, K. McCafferty, A. DePalma (AlixPartners), R. Schnitzler (PJT) and Creditor Committee members re: Project Catalyst. | 0.50 |
| 09/03/20 | ADD | Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: materials agreements and excluded contracts for schedules. | 0.20 |
| 09/03/20 | ADD | Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence. | 0.30 |
| 09/03/20 | KM | Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence. | 0.30 |
| 09/03/20 | KM | Call with D. Fogel, W. DiNicola (both Purdue) re: supply agreements schedules review. | 0.10 |
| 09/03/20 | KM | Analysis re: employee retention costs. | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/03/20 | KM | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: document and negotiations review. | 1.30 |
| 09/03/20 | KM | Call with D. Fogel (Purdue) re: analysis of offered employees. | 0.30 |
| 09/03/20 | JD | Call with J. Lowne (Purdue) re: team call follow-up. | 0.50 |
| 09/03/20 | JD | Call with J. Lowne, E. Ruiz, S. Danil (all Purdue) re: contract analysis. | 0.50 |
| 09/03/20 | JD | Call with R. Schnitzler, J. Turner, T. Melvin (all PJT), M. Atkinson (Province), M. Diaz, B. Bromberg (both FTI), L. Szlenzinger (Jefferies), G. Coutts, H. Schenk (Houlihan), J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: Catalyst update. | 0.50 |
| 09/03/20 | JD | Review draft professional fees for August accruals. | 0.40 |
| 09/03/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: RT/RP agreements. | 2.50 |
| 09/03/20 | HSB | Review KEIP/KERP motion. | 0.40 |
| 09/03/20 | GJK | Review updated variances by product category in revised Mundipharma model. | 1.00 |
| 09/03/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) re: prep for call with J Turner (PJT). | 0.20 |
| 09/03/20 | NAS | Finalize Mundipharma Risk-Adjusted Case variance analysis to share with PJT. | 1.20 |
| 09/03/20 | NAS | Draft list of key Mundipharma information provided since first iteration of diligence report. | 0.30 |
| 09/03/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) re: prep for call with J Turner (PJT). | 0.20 |
| 09/04/20 | GJK | Call with J Turner (PJT) re: Mundipharma model updates, | 0.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | include prep time. | |
| 09/04/20 | JD | Discussion with D. Sims (Willis Towers) re: KEIP/KERP motion. | 0.90 |
| 09/04/20 | JD | Discussion with J. Lowne (Purdue) re: KEIP/KERP reductions. | 0.30 |
| 09/04/20 | JD | Correspondence with Davis Polk re: comments on the latest KEIP/KERP motions and declaration. | 0.80 |
| 09/04/20 | JD | Update the wage summary analysis to capture additional LTRP participants. Correspondence with Province re: same. | 1.30 |
| 09/04/20 | JD | Correspondence with K. Laurel (Purdue) re: remote working. Review employee roster re: same. | 0.40 |
| 09/04/20 | JD | Correspondence with J. Lowne (Purdue) re: LTRP reduction analysis. | 0.70 |
| 09/04/20 | JD | Mark-up of the latest KEIP motion and send out to the group. | 0.60 |
| 09/04/20 | JD | Update professional fee accruals for June and July. | 0.40 |
| 09/04/20 | JD | Review and provide comments to the latest Lowne declaration re: KEIP. | 0.80 |
| 09/04/20 | JD | Calculate pre-2018 performance amounts for Insiders. | 0.60 |
| 09/04/20 | KM | Analysis re: COVID pay premium for RT employees. | 0.40 |
| 09/04/20 | KM | Meeting with D. Lundie, K. McCarthy, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Project Catalyst call debrief. | 0.80 |
| 09/04/20 | KM | Call with R. Aleali (Purdue) re: compensation schedules and VDR files for Catalyst. | 0.30 |
| 09/04/20 | KM | Analysis re: supply agreements for Catalyst. | 0.50 |
| 09/04/20 | KM | Call with R. Shamblen (Purdue) and A. Gallogly | 0.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | (Skadden) re: APA schedules for project Catalyst. | |
| 09/04/20 | KM | Call with J. Lowne (Purdue) and R. Schnitzler (PJT) re: COVID pay premium programmed. | 0.20 |
| 09/04/20 | KM | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Project Catalyst document and negotiations review. | 1.60 |
| 09/04/20 | KM | Analysis re: COVID pay premium for RT employees. | 1.10 |
| 09/04/20 | KM | Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract diligence status. | 0.20 |
| 09/04/20 | ADD | Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract diligence status. | 0.20 |
| 09/04/20 | KM | Analysis and updates re: project Catalyst schedules and exhibits. | 1.70 |
| 09/04/20 | KM | Respond and update schedules re: project Catalyst. | 1.10 |
| 09/04/20 | KM | Analysis re: cure costs and RT purchases for project Catalyst. | 2.40 |
| 09/04/20 | KM | Manage and edit schedules and file for VDR re: project Catalyst. | 1.20 |
| 09/04/20 | KM | Call with R. Schnitzler (PJT), Project Catalyst diligence team re: COVID pay premium and other updates. | 0.30 |
| 09/04/20 | ADD | Compile SAP data and update liabilities subject to compromise report for August. | 2.60 |
| 09/05/20 | JD | Correspondence with C. DeStefano (Purdue) and D. Consla (Davis Polk) re: KEIP/KERP questions. | 0.30 |
| 09/06/20 | JD | Correspondence with R. Aleali (Purdue) re: material contract review. | 0.30 |
| 09/06/20 | JD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: APA and MSA | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | schedules. | |
| 09/06/20 | JD | Mark-up of the latest version of the Lowne declaration re: KEIP. | 0.70 |
| 09/06/20 | JD | Discussion with M. Huebner (Davis Polk) re: KEIP motion. | 0.10 |
| 09/06/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: APA and MSA schedules. | 0.60 |
| 09/07/20 | KM | Meeting with K. McCafferty, A. DePalma (both AlixPartners), D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Project Catalyst document and negotiations review. | 0.50 |
| 09/07/20 | KM | Meeting with W. DiNicola, D. Fogel, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: prorated expenses and cure costs for Catalyst. | 0.50 |
| 09/07/20 | KM | Analysis re: APA prorated expenses. | 0.30 |
| 09/07/20 | KM | Call with R. Schnitzler (PJT) re: employee compensation for project Catalyst. | 0.10 |
| 09/07/20 | KM | Analysis re: open RT POs. | 1.80 |
| 09/07/20 | KM | Coordinate and update VDR and supplier contracts re: project Catalyst. | 2.00 |
| 09/07/20 | KM | Analysis re: RT 2020 purchases and agreements for project Catalyst. | 1.60 |
| 09/07/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: APA and MSA schedules. | 1.30 |
| 09/07/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: APA and MSA schedules. | 1.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/07/20 | ADD | Meeting with K. McCafferty, A. DePalma (both AlixPartners), D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Project Catalyst document and negotiations review. | 0.50 |
| 09/07/20 | ADD | Meeting with W. DiNicola, D. Fogel, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: prorated expenses and cure costs for Catalyst. | 0.50 |
| 09/07/20 | JD | Analyze break down of compensation agreements by company. | 1.10 |
| 09/07/20 | JD | Correspondence with M. Atkinson (Province) re: KEIP/KERP diligence questions. | 0.40 |
| 09/07/20 | JD | Correspondence with Davis Polk and Purdue re: Project Catalyst. | 0.50 |
| 09/07/20 | JD | Correspondence with Davis Polk and Willis Towers Watson re: open diligence questions from FTI and Province. | 0.60 |
| 09/07/20 | LJD | Review prereads for board meeting | 1.20 |
| 09/08/20 | LJD | Participate in PPI Board meeting including L. Donahue and J. DelConte (both AlixPartners) in attendance. | 1.10 |
| 09/08/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to review latest draft of Mundipharma business plan model and plan priorities for week. | 0.80 |
| 09/08/20 | NAS | Implement final revisions to Mundipharma business plan model prior to sharing with PJT. | 2.00 |
| 09/08/20 | NAS | Add downside case to Mundipharma business plan model. | 1.20 |
| 09/08/20 | NAS | Draft cover note for Mundipharma business plan model and share materials with PJT. | 1.50 |
| 09/08/20 | JD | Correspondence with Davis Polk, Willis Towers Watson and Province re: open KEIP/KERP questions. | 0.80 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/08/20 | JD | Correspondence with Davis Polk re: getting Project Catalyst and KEIP/KERP documents uploaded to the dataroom. | 0.40 |
| 09/08/20 | JD | Correspondence with Davis Polk and PJT re: long term bonuses and Project Catalyst. | 0.30 |
| 09/08/20 | JD | Review latest draft of the APA and Supply Agreement for Project Catalyst. | 1.00 |
| 09/08/20 | JD | Meeting with K. McCafferty, J. DelConte and A. DePalma (all AlixPartners) re: cure costs for project Catalyst. | 0.50 |
| 09/08/20 | JD | Review latest draft Project Catalyst sale order. | 0.60 |
| 09/08/20 | GJK | Plan and coordinate for updating Mundipharma final report. | 2.50 |
| 09/08/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to review latest draft of Mundipharma business plan model and plan priorities for week. | 0.80 |
| 09/08/20 | GJK | Review Mundipharma model variances and potential updates to report. | 2.80 |
| 09/08/20 | GJK | Review strong opioids across markets. | 2.00 |
| 09/08/20 | ADD | Compile, review and request approval to upload document to the Project Catalyst data room. | 2.10 |
| 09/08/20 | ADD | Meeting with J .Doyle, D. Fogel, E. Ruta, K. McCarthy (all Purdue), A. Gallogly, M. Gibson, M. Sumner, R. Schlossberg (all Skadden), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst schedules. | 1.20 |
| 09/08/20 | ADD | Meeting with W. DiNicola, D. Fogel, (Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Cure Costs Discussion. | 0.40 |
| 09/08/20 | ADD | Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence questions review. | 0.20 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/08/20 | ADD | Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence. | 1.00 |
| 09/08/20 | ADD | Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: vendor activities associated with cure costs. | 0.70 |
| 09/08/20 | ADD | Meeting with K. McCafferty, J. DelConte and A. DePalma (all AlixPartners) re: cure costs for project Catalyst. | 0.50 |
| 09/08/20 | KM | Meeting with J. Doyle, D. Fogel, E. Ruta, K. McCarthy (all Purdue), A. Gallogly, M. Gibson, M. Sumner, R. Schlossberg (all Skadden), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst schedules. | 1.20 |
| 09/08/20 | KM | Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: vendor activities associated with cure costs. | 0.70 |
| 09/08/20 | KM | Analysis re: project Catalyst savings. | 0.50 |
| 09/08/20 | KM | Meeting with W. DiNicola, D. Fogel, (Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Cure Costs Discussion. | 0.40 |
| 09/08/20 | KM | Review re: outstanding purchases and cure costs for project Catalyst. | 0.70 |
| 09/08/20 | KM | Call with J. Lowne (Purdue) re: cure costs for Catalyst. | 0.10 |
| 09/08/20 | KM | Analysis re: outstanding purchases and cure costs for project Catalyst. | 1.70 |
| 09/08/20 | KM | Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence. | 1.00 |
| 09/08/20 | KM | Meeting with K. McCafferty, J. DelConte and A. DePalma (all AlixPartners) re: cure costs for project Catalyst. | 0.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/08/20 | KM | Analysis re: open RT POs. | 1.80 |
| 09/08/20 | KM | Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence questions review. | 0.20 |
| 09/08/20 | KM | Call with D. Fogel (Purdue) re: Project Catalyst deal analysis and bridge to April 2020 business plan. | 1.10 |
| 09/08/20 | KM | Analysis re: volume and pricing impact of Catalyst offer versus April 2020 budget. | 0.90 |
| 09/08/20 | JD | Participate in PPI Board meeting including L. Donahue and J. DelConte (both AlixPartners) in attendance. | 1.10 |
| 09/08/20 | JD | Call with J. Lowne (Purdue) re: Project Catalyst. | 0.30 |
| 09/09/20 | KM | Call with D. Fogel, W. DiNicola (both Purdue) re: offer versus Base Case analysis for Catalyst. | 0.60 |
| 09/09/20 | KM | Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (Purdue), A. DePalma (AlixPartners) re: open POs in SAP and Ariba for Catalyst. | 1.40 |
| 09/09/20 | KM | Analysis re: API pricing and volume impact of Catalyst savings. | 1.00 |
| 09/09/20 | KM | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, M. Gibson (all Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst update and document review. | 0.90 |
| 09/09/20 | KM | Review of disclosure schedules re: project Catalyst. | 0.70 |
| 09/09/20 | KM | Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update discussion. | 0.40 |
| 09/09/20 | KM | Analysis and schedule updates re: project Catalyst. | 1.20 |
| 09/09/20 | KM | Call with D. Fogel, W. DiNicola (both Purdue) re: Api pricing versus base case. | 1.30 |
| 09/09/20 | KM | Analysis re: API pricing and volume impact of Catalyst | 0.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | savings. | |
| 09/09/20 | KM | Create schedule of critical open RT POs re: project Catalyst. | 1.10 |
| 09/09/20 | KM | Analysis re: open PO data for schedules for Catalyst. | 1.70 |
| 09/09/20 | ADD | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, M. Gibson (all Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst update and document review. | 0.90 |
| 09/09/20 | ADD | Review and compile contracts for external counsel review. | 1.90 |
| 09/09/20 | ADD | Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update discussion. | 0.40 |
| 09/09/20 | ADD | Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: re: open POs in SAP and Ariba for Catalyst. | 1.40 |
| 09/09/20 | GJK | Review of Mundipharma slides for updates. | 2.50 |
| 09/09/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners), J. Turner (PJT), and J. Arsic (PJT) to review latest draft of Mundipharma business plan model. | 0.70 |
| 09/09/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to review necessary changes to Key Findings section of draft Mundipharma diligence report. | 0.50 |
| 09/09/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to review edits to Mundipharma diligence report and note additional changes to be made. | 1.30 |
| 09/09/20 | JD | Review and edit responses from management to various open KEIP/KERP creditor inquiries. | 0.50 |
| 09/09/20 | JD | Review latest WTW declaration to be filed with the KEIP/KERP motion. | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/09/20 | JD | Review the latest J. Lowne (Purdue) declaration re: KEIP/KERP motion. | 0.70 |
| 09/09/20 | JD | Update employee and compensation trackers in order to capture recent hires. | 0.80 |
| 09/09/20 | JD | Review list of termed employees and previous bonus payments. | 1.00 |
| 09/09/20 | JD | Review HRT updates prior to uploading them to the dataroom. | 0.80 |
| 09/09/20 | JD | Meeting with R. Aleali, J. Lowne, E. Ruiz and S. Daniel (all Purdue) re: contract review. | 0.60 |
| 09/09/20 | JD | Call with C. Oluwole (Davis Polk) re: UCC presentation. | 0.10 |
| 09/09/20 | JD | Review Purdue compensation committee presentation. | 0.70 |
| 09/09/20 | JD | Review CTC board resolutions. | 0.30 |
| 09/09/20 | JD | Correspondence with C. DeStefano (Purdue) re: process for updating AIP and LTRP trackers. | 0.50 |
| 09/09/20 | NAS | Respond to diligence question re: Mundipharma Board structure. | 0.40 |
| 09/09/20 | NAS | Prepare for Mundipharma model walk-through with PJT. | 0.40 |
| 09/09/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners), J. Turner (PJT), and J. Arsic (PJT) to review latest draft of Mundipharma business plan model. | 0.70 |
| 09/09/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to review necessary changes to Key Findings section of draft Mundipharma diligence report. | 0.50 |
| 09/09/20 | NAS | Revise Key Findings section of Mundipharma diligence report per latest model. | 1.90 |
| 09/09/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to review edits to Mundipharma diligence report and note additional changes to be made. | 1.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/10/20 | NAS | Revisions to Mundipharma Business Plan Overview section of diligence report. | 2.90 |
| 09/10/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to walk through risk adjustment slides. | 1.20 |
| 09/10/20 | NAS | Add individual product P&Ls to latest draft of Mundipharma business plan model. | 0.70 |
| 09/10/20 | NAS | Build comparison of Mundipharma 2020 Original Budget to latest forecast for inclusion in diligence report. | 1.60 |
| 09/10/20 | JD | Correspondence with Davis Polk and PJT re: comments on the illustrative settlement cash flow forecast. | 0.40 |
| 09/10/20 | JD | Review presentations presented to the UCC per a Davis Polk request. | 0.70 |
| 09/10/20 | JD | Follow up correspondence with WTW re: open FTI diligence questions on KEIP/KERP. | 0.50 |
| 09/10/20 | JD | Correspondence with PJT re: draft illustrative settlement cash flow forecast. | 0.30 |
| 09/10/20 | JD | Discussion with C. DeStefano (Purdue) re: KERP promo calculation examples. | 0.60 |
| 09/10/20 | JD | Correspondence with PJT and Purdue re: follow-up conversation with M. Burke. | 0.30 |
| 09/10/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to walk through risk adjustment slides. | 1.20 |
| 09/10/20 | GJK | Review key findings slides for potential updates. | 2.50 |
| 09/10/20 | GJK | Review prior working capital/cash flows/balance sheet information to plan for updated projections from Mundipharma. | 1.50 |
| 09/10/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract review and analysis. | 1.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/10/20 | ADD | Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel (all Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting. | 1.20 |
| 09/10/20 | RDS | Call with K. McCafferty, R. Sublett (both AlixPartners) re: April Rt closure plan and impact on project Catalyst savings. | 0.50 |
| 09/10/20 | KM | Analysis and review re: association of Cure POs to supply agreements for Catalyst. | 1.10 |
| 09/10/20 | KM | Analysis and savings bridge re: project Catalyst versus April 2020 Budget. | 2.30 |
| 09/10/20 | KM | Call with A. Gallogly (Skadden) re: purchase orders required for project Catalyst. | 0.20 |
| 09/10/20 | KM | Meeting with D. Fogel (Purdue) re: savings bridge from April budget to current catalyst proposal. | 0.50 |
| 09/10/20 | KM | Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel (all Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting. | 1.20 |
| 09/10/20 | KM | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg (Skadden) re: Catalyst update and document review. | 1.00 |
| 09/10/20 | KM | Analysis API pricing impact re: Noramco offer for project Catalyst. | 0.90 |
| 09/10/20 | KM | Analysis and review re: documentation of supply agreements for schedules. | 0.50 |
| 09/10/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract review and analysis. | 1.50 |
| 09/10/20 | KM | Analysis or RT versus RT contracts re: project Catalyst. | 0.80 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/10/20 | KM | Meeting with D. Fogel (Purdue) re: Catalyst savings impact over April budget. | 0.70 |
| 09/10/20 | KM | Update savings calculations re: project Catalyst. | 0.40 |
| 09/10/20 | KM | Call with K. McCafferty, R. Sublett (both AlixPartners) re: April Rt closure plan and impact on project Catalyst savings. | 0.50 |
| 09/11/20 | KM | Analysis and research re: RT agreements for project Catalyst. | 0.70 |
| 09/11/20 | KM | Call with D. Fogel, J. Lowne (both Purdue), and R. Schnitzler (PJT) re: Catalyst savings impact review. | 0.50 |
| 09/11/20 | KM | Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: open POs in SAP and Ariba for Catalyst. | 1.40 |
| 09/11/20 | KM | Analysis re: project Catalyst supply schedules. | 0.80 |
| 09/11/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence production. | 1.30 |
| 09/11/20 | KM | Review and editing re: project Catalyst schedules and exhibits. | 1.20 |
| 09/11/20 | KM | Call M. Gibson, A. Gallogly (Skadden), J. Doyle, K. McCarthy (both Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst - Revised APA (IP Comments) and supply agreements. | 0.80 |
| 09/11/20 | KM | Call with D. Fogel, J. Dolye, R. Shamblen (all Purdue) re: agreements and materiality for project Catalyst. | 0.70 |
| 09/11/20 | KM | Analysis re: project Catalyst material supply agreements. | 0.40 |
| 09/11/20 | KM | Call with R. Schnitzler (PJT) re: project Catalyst financial impact and savings. | 0.60 |
| 09/11/20 | KM | Update schedules re: project Catalyst. | 0.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/11/20 | KM | Call with R. Shamblen, D. Fogel, J. Doyle, A. Nadeau, A. Soma (Purdue), K. McCarthy (Purdue), A. Gallogly (Skadden), and A. DePalma (AlixPartners) re: finalization of schedules for project Catalyst. | 1.10 |
| 09/11/20 | JD | Call with B. Leuchter, R. Schnitzler, J. Turner (all PJT) and T. McDonnell (BW Health) re: Adhansia. | 0.50 |
| 09/11/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence production | 1.30 |
| 09/11/20 | ADD | Research contracts/agreements for potential inclusion in the schedules and release to the bidders as part of diligence. | 2.80 |
| 09/11/20 | ADD | Compile and upload materials in response to diligence requests for upload to the Project Catalyst data room. | 2.30 |
| 09/11/20 | ADD | Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: open POs in SAP and Ariba for Catalyst. | 1.40 |
| 09/11/20 | ADD | Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta, R. Shamblen, A. Soma, A. Nadeau (Purdue), K. McCarthy (Purdue), A. DePalma (AlixPartners) re: Finalization of the contract list. | 1.10 |
| 09/11/20 | ADD | Call M. Gibson, A. Gallogly (Skadden), J. Doyle, K. McCarthy (both Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst - Revised APA (IP Comments) and supply agreements. | 0.80 |
| 09/11/20 | GJK | Review LEK commercial report for Mundipharma. | 3.00 |
| 09/11/20 | GJK | Review updates Tech Ops cost reduction targets and compare to original Tech Ops plan provided to BoardZ | 1.60 |
| 09/11/20 | GJK | Scan updated Malta model for variances. | 2.00 |
| 09/11/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to share | 1.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | initial takeaways from review of Summary LEK/Mundipharma Commercial Due Diligence Report. | |
| 09/11/20 | JD | Correspondence with Purdue re: KEIP/KERP calculation questions. | 0.40 |
| 09/11/20 | JD | Correspondence with Province re: open KEIP/KERP calculation questions. | 0.30 |
| 09/11/20 | JD | Call with S. Hinden (Willis Towers) re: open FTI KEIP/KERP questions. | 0.20 |
| 09/11/20 | JD | Call with R. Aleali (Purdue) re: open KEIP/KERP questions. | 0.50 |
| 09/11/20 | JD | Review draft business plan to present to the creditors per the August business plan refresh. | 0.60 |
| 09/11/20 | JD | Review this month's Nalmafene reporting and correspondence from Purdue re: same. | 0.40 |
| 09/11/20 | JD | Review updated draft Project Catalyst sale motion and declaration. | 0.80 |
| 09/11/20 | NAS | Review summary Mundipharma/LEK Commercial Due Diligence Report. | 2.50 |
| 09/11/20 | NAS | Analyze key products not assessed in Summary Mundipharma/LEK Commercial Due Diligence Report. | 1.00 |
| 09/11/20 | NAS | Build overview of working capital ratios included in latest Mundipharma management forecast. | 0.80 |
| 09/11/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to share initial takeaways from review of Summary LEK/Mundipharma Commercial Due Diligence Report. | 1.50 |
| 09/12/20 | JD | Correspondence with Davis Polk and Purdue re: contract notice parties. | 0.30 |
| 09/12/20 | JD | Prepare responses to certain business questions from the Monitor. | 0.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/12/20 | JD | Correspondence with PJT re: open questions from the UCC on Project Catalyst. | 0.20 |
| 09/12/20 | JD | Review new KEIP/KERP questions from FTI. Draft and send an initial set of responses. | 0.80 |
| 09/12/20 | KM | Analysis re: materials contracts for project Catalyst. | 1.30 |
| 09/12/20 | KM | Analysis re: post petition POs for Catalyst. | 2.20 |
| 09/13/20 | KM | Analysis re: PO obligations for project Catalyst. | 0.70 |
| 09/13/20 | KM | Analysis re: post petition POs for Catalyst. | 2.40 |
| 09/13/20 | KM | Analysis re: identifying notice parties. | 1.40 |
| 09/14/20 | KM | Analysis and tracking re: post-petition contracts for Catalyst. | 1.70 |
| 09/14/20 | KM | Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: open POs in SAP and Ariba for Catalyst. | 0.40 |
| 09/14/20 | KM | Analysis and research re: post-petition contracts. | 1.10 |
| 09/14/20 | KM | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, M. Gibson (all Skadden) re: pre-signing review call. | 0.40 |
| 09/14/20 | KM | Review and edits re: project Catalyst schedules. | 1.10 |
| 09/14/20 | KM | Manage supply agreements re: project Catalyst. | 1.10 |
| 09/14/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract review and analysis. | 0.80 |
| 09/14/20 | KM | Review of documents and schedules re: project Catalyst. | 1.30 |
| 09/14/20 | KM | Call with K. McCafferty and J. DelConte (both AlixPartners) re: Project Catalyst PMO. | 0.30 |
| 09/14/20 | ADD | Virtual working session with A. DePalma and K. | 0.80 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | McCafferty (both AlixPartners) re: Project Catalyst contract review and analysis. | |
| 09/14/20 | ADD | Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: open POs in SAP and Ariba for Catalyst. | 0.40 |
| 09/14/20 | JD | Call with J. Lowne, C. DeStefano (both Purdue) re: LTRP accounting. | 0.40 |
| 09/14/20 | JD | Call with M. Kesselman, R. Aleali, J. Lowne (both Purdue), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte (both AlixPartners) re: follow-up with M. Burke (BTCP Pharma). | 0.60 |
| 09/14/20 | JD | Call with K. McCafferty and J. DelConte (both AlixPartners) re: Project Catalyst PMO. | 0.30 |
| 09/14/20 | JD | Review and provide comments on the August business plan refresh presentation to share with creditors. | 0.70 |
| 09/14/20 | JD | Prepare draft responses to the AHC diligence questions on the KEIP / KERP and correspondence with Davis Polk and Willis Towers Watson re: same. | 1.50 |
| 09/14/20 | JD | Prepare analysis of retention participants by subarea and 2020 insider bonus payments. | 1.00 |
| 09/14/20 | JD | Review details on investigation hours per Davis Polk request. | 0.50 |
| 09/14/20 | JD | Review list of contract counterparties and notice addresses for Project Catalyst. | 0.30 |
| 09/14/20 | JD | Review analysis of API's to be sourced from Project Catalyst per UCC requests. | 0.30 |
| 09/14/20 | JD | Review updated August plan refresh to be shared with the creditor advisors. | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/14/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) re: takeaways from initial review of revised Mundipharma working capital projections. | 1.10 |
| 09/14/20 | GJK | Review new Mundipharma balance sheets. | 2.50 |
| 09/14/20 | GJK | Review Mundipharma model updates. | 2.00 |
| 09/14/20 | NAS | Review working capital projections in latest Mundipharma Balance Sheet/Cash Flow Statement. | 1.40 |
| 09/14/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) re: takeaways from initial review of revised Mundipharma working capital projections. | 1.10 |
| 09/14/20 | NAS | Compare Mundipharma working capital projections from latest forecast to prior version provided in March. | 1.60 |
| 09/14/20 | NAS | Draft Mundipharma net working capital overview for PJT. | 1.60 |
| 09/14/20 | LJD | Call with M. Kesselman, R. Aleali, J. Lowne (both Purdue), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte (both AlixPartners) re: follow-up with M. Burke (BTCPharma). | 0.60 |
| 09/15/20 | NAS | Draft Mundipharma FCF overview for PJT based on latest management Balance Sheet and Cash Flow Statement. | 2.50 |
| 09/15/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to review net working capital overview to be sent to PJT. | 0.60 |
| 09/15/20 | NAS | Draft list of questions for 9/16 call with A. Breabout (Purdue). | 0.40 |
| 09/15/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to review net working capital overview to be sent to PJT. | 0.60 |
| 09/15/20 | GJK | Plan and coordinate Mundipharma analysis updates. | 2.50 |
| 09/15/20 | JD | Prepare list of employees related to Project Catalyst. | 0.70 |
| 09/15/20 | JD | Call with A. DePalma, J. DelConte and K. McCafferty (all | 0.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/15/20 | JD | AlixPartners) re: Project Catalyst status discussion | 0.40 |
| 09/15/20 | JD | Correspondence with Province re: Project Catalyst API sourcing questions. | 0.30 |
| 09/15/20 | JD | Correspondence with C. DeStefano (Purdue) re: KEIP/KERP calculations. | 0.60 |
| 09/15/20 | JD | Review go-forward plan from C. DeStefano (Purdue) re: remainder of 2020 LTRP and AIP calculations. | 0.40 |
| 09/15/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst schedule follow ups. | 0.50 |
| 09/15/20 | ADD | Call with A. DePalma, J. DelConte and K. McCafferty (all AlixPartners) re: Project Catalyst status discussion | 1.60 |
| 09/15/20 | ADD | Download and compile source data for Purdue liquidation analysis model. | 2.10 |
| 09/15/20 | ADD | Review accounting data to develop liquidation analysis assumption. | 3.10 |
| 09/15/20 | ADD | Review Rhodes vendor analysis to identify and classify by entity any Rhodes contracts. | 1.70 |
| 09/15/20 | KM | Update and review operations and supply chain transition activities re: project Catalyst. | 0.40 |
| 09/15/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst schedule follow ups. | 1.20 |
| 09/15/20 | KM | Develop required action list re: post signing for Rhodes and Purdue. | 0.80 |
| 09/15/20 | KM | Prepare transition planning workplan re: project Catalyst. | 0.50 |
| 09/15/20 | KM | Call with A. DePalma, J. DelConte and K. McCafferty (all AlixPartners) re: Project Catalyst status discussion | 0.90 |
| 09/15/20 | KM | Analysis re: project Catalyst post-signing activities. | |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/15/20 | KM | Analysis re: final API sourcing outcome and financial impact. | 1.50 |
| 09/16/20 | KM | Call D. Fogel (Purdue), A. DePalma and K. McCafferty (AlixPartners) re: RT and RP contracts for Chapter 11 emergence. | 0.70 |
| 09/16/20 | KM | Analysis and document preparation re: Catalyst transition plan and program management structure. | 2.50 |
| 09/16/20 | KM | Call with D. Lundie, D. Fogel, J. Lowne (all Purdue), J. DelConte, A. DePalma, K. McCafferty (all AlixPartners) re: project Catalyst transition planning. | 0.50 |
| 09/16/20 | KM | Analysis and workplan development re: project Catalyst transition plan. | 1.40 |
| 09/16/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst post signing work plan development discussion. | 1.20 |
| 09/16/20 | KM | Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence. | 0.30 |
| 09/16/20 | KM | Creation documents re: Catalyst transition plan. | 0.70 |
| 09/16/20 | KM | Analysis and coordination re: outstanding diligence requests. | 1.30 |
| 09/16/20 | KM | Call with K. McCafferty, J. DelConte (both AlixPartners) re: Project Catalyst work plan. | 0.40 |
| 09/16/20 | ADD | Call with A. DePalma, J. DelConte (both AlixPartners) re: next steps for Project Catalyst. | 0.30 |
| 09/16/20 | ADD | Call with R. Aleali, K. McCarthy, B. Miller (all Purdue), A. Lele, E. Diggs, E. Vonnegut, C. Robertson, W. Taylor (all Davis Polk), M. Florence, J. Bragg (both Skadden), J. Turner, T. Melvin (both PJT), J. DelConte, A. DePalma (both AlixPartners) re: contract transfers. | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/16/20 | ADD | Call D. Fogel (Purdue), A. DePalma and K. McCafferty (AlixPartners) re: RT and RP contracts for Chapter 11 emergence. | 0.70 |
| 09/16/20 | ADD | Call with D. Lundie, D. Fogel, J. Lowne (all Purdue), J. DelConte, A. DePalma, K. McCafferty (all AlixPartners) re: project Catalyst transition planning. | 0.50 |
| 09/16/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst post signing work plan development discussion. | 1.20 |
| 09/16/20 | ADD | Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence. | 0.30 |
| 09/16/20 | JD | Call with R. Aleali, K. McCarthy, B. Miller (all Purdue), A. Lele, E. Diggs, E. Vonnegut, C. Robertson, W. Taylor (all Davis Polk), M. Florence, J. Bragg (both Skadden), J. Turner, T. Melvin (both PJT), J. DelConte, A. DePalma (both AlixPartners) re: contract transfers. | 0.60 |
| 09/16/20 | JD | Call with J. Lowne (Purdue) re: KEIP/KERP accounting. | 0.30 |
| 09/16/20 | JD | Call with A. DePalma, J. DelConte (both AlixPartners) re: next steps for Project Catalyst. | 0.30 |
| 09/16/20 | JD | Call with K. McCafferty, J. DelConte (both AlixPartners) re: Project Catalyst work plan. | 0.40 |
| 09/16/20 | JD | Correspondence with Davis Polk and Purdue re: Nalmafene reporting. | 0.30 |
| 09/16/20 | JD | Prepare for and participate in call with J. Lowne, D. Lundie, D. Fogel (all Purdue), K. McCafferty, J. DelConte, A. DePalma (all AlixPartners) re: Project Catalyst transition planning. | 0.70 |
| 09/16/20 | JD | Analyze differences between current 2020 retention award amounts and amounts provided to creditors last | 1.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | year. | |
| 09/16/20 | JD | Update LTRP tracker for 3 additional participants / payments. | 0.40 |
| 09/16/20 | JD | Update latest professional fee tracker for Davis Polk in advance of the preliminary injunction hearing. | 0.50 |
| 09/16/20 | JD | Review and calculate annual AIP accruals for Purdue, Rhodes Pharma and Rhodes Tech. | 0.70 |
| 09/16/20 | JD | Correspondence with E. Vonnegut (Davis Polk) re: UCC KEIP/KERP feedback. | 0.30 |
| 09/16/20 | JD | Draft list of ongoing company workstreams in advance of potential KEIP/KERP objection reply. | 0.80 |
| 09/16/20 | GJK | Prepare for call with A Breabout (Purdue) to recede 2Q 2020 performance. | 1.50 |
| 09/16/20 | GJK | Mundipharma diligence call with A. Breabout (Purdue), G. Koch, N. Simon (both AlixPartners), and other diligence advisors. | 1.10 |
| 09/16/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic, I. Mian (all PJT) to review changes in Mundipharma net working capital implied by latest management forecast. | 0.70 |
| 09/16/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) re: variance between latest iterations of Mundipharma management forecast. | 0.30 |
| 09/16/20 | GJK | Analyze 2H performance trend to Mundipharma business plan. | 2.00 |
| 09/16/20 | GJK | Review product category trends in Mundipharma model and business update. | 2.00 |
| 09/16/20 | NAS | Build variance between latest versions of Mundipharma management forecast and investigate changes. | 1.40 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/16/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) re: variance between latest iterations of Mundipharma management forecast. | 0.30 |
| 09/16/20 | NAS | Prepare for meeting with A. Breabout (Purdue). | 0.70 |
| 09/16/20 | NAS | Mundipharma diligence call with A. Breabout (Purdue), G. Koch, N. Simon (both AlixPartners), and other diligence advisors. | 1.10 |
| 09/16/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic, I. Mian (all PJT) to review changes in Mundipharma net working capital implied by latest management forecast. | 0.70 |
| 09/17/20 | NAS | Draft and send follow-up questions re: latest Mundipharma forecast provided by company. | 0.60 |
| 09/17/20 | LJD | Preread materials for special committee call | 0.80 |
| 09/17/20 | LJD | Attend special committee call | 0.40 |
| 09/17/20 | GJK | Compare market level balance sheet and cash flows. | 2.50 |
| 09/17/20 | GJK | Review Mundipharma diligence documents for product category working capital assumptions. | 2.20 |
| 09/17/20 | GJK | Review Mundipharma FCF assumptions. | 2.00 |
| 09/17/20 | JD | Call with R. Aleali (Purdue) re: post-call catch up. | 0.20 |
| 09/17/20 | JD | Prepare for and participate in PPI board meeting. | 0.60 |
| 09/17/20 | JD | Update professional fee tracker for M. Huebner (Davis Polk). | 0.30 |
| 09/17/20 | JD | Correspondence with Davis Polk re: additional AIP related to OT and shift differentials for hourly employees. | 0.50 |
| 09/17/20 | JD | Correspondence with C. DeStefano and D. Warren (both Purdue) re: additional AIP for OT and shift differential. | 0.60 |
| 09/17/20 | JD | Correspondence with M. Kesselman (Purdue) re: latest | 0.20 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | bankruptcy costs. | |
| 09/17/20 | JD | Call led by Debevoise re: Side A Sackler distributions. | 0.80 |
| 09/17/20 | JD | Review latest Project Catalyst workplan. | 0.30 |
| 09/17/20 | JD | Correspondence with Purdue re: open critical vendor invoices. | 0.30 |
| 09/17/20 | JD | Review draft July monthly flash report prior to providing to creditors. | 0.60 |
| 09/17/20 | ADD | Review and analyze Rhodes contracts for materiality and relative importance. | 1.00 |
| 09/17/20 | KM | Review documents re: project Catalyst transition plan. | 1.60 |
| 09/17/20 | KM | Analysis and workplan development re: project Catalyst transition plan. | 2.20 |
| 09/17/20 | KM | Analysis re: RP active contracts. | 2.80 |
| 09/17/20 | KM | Call with D. Fogel (Purdue) and A. DePalma., K. McCafferty (AlixPartners) re: RP contract analysis results. | 0.90 |
| 09/17/20 | KM | Analysis and tracking re: post-petition contracts for Catalyst. | 0.10 |
| 09/18/20 | KM | Create transition kickoff documents re: project Catalyst. | 0.60 |
| 09/18/20 | KM | Edit documents re: Catalyst transition plan. | 1.10 |
| 09/18/20 | KM | Create milestone tracker re: Catalyst transition. | 1.60 |
| 09/18/20 | KM | Analysis re: executory contracts and supply agreements for Catalyst. | 1.20 |
| 09/18/20 | ADD | Download and compile accounting data for liquidation analysis. | 1.70 |
| 09/18/20 | JD | Correspondence with Purdue and Davis Polk re: LTRP for retirees. | 0.80 |
| 09/18/20 | JD | Review draft responses from the creditors on KEIP/KERP. Analyze effects on various employee groups. | 1.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/18/20 | JD | Review latest draft Project Catalyst transition work plan. | 0.30 |
| 09/18/20 | JD | Review Side A distribution detail excels. | 0.50 |
| 09/18/20 | JD | Prepare KEIP/KERP accounting summary for Purdue for J. Lowne (Purdue) | 2.60 |
| 09/18/20 | JD | Prepare KEIP/KERP accounting summary for Rhodes for J. Lowne (Purdue). | 1.50 |
| 09/18/20 | JD | Call with E. Vonnegut (Davis Polk) re: UCC KEIP/KERP response. | 0.20 |
| 09/18/20 | GJK | Plan and coordinate for Mundipharma risk adjustment section of report. | 1.90 |
| 09/18/20 | GJK | Review Mundipharma net working capital trends and supporting historical information. | 3.00 |
| 09/18/20 | GJK | Review key open questions for diligence. | 1.50 |
| 09/18/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to review Mundipharma net working capital analysis. | 0.70 |
| 09/18/20 | LJD | Update call with J. Dubel (Board Member) | 0.40 |
| 09/18/20 | SKL | Review July financials presentation and began making updates to the July Flash report accordingly. | 2.10 |
| 09/18/20 | NAS | Review discrepancy in Mundipharma Other Charges P&L line in data provided. | 0.70 |
| 09/18/20 | NAS | Review Mundipharma diligence documents for information on inventory by product line. | 1.70 |
| 09/18/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to review Mundipharma net working capital analysis. | 0.70 |
| 09/18/20 | IA | Reviewed Purdue retention information to validate participant payments to be made in October. | 1.10 |
| 09/18/20 | NAS | Review new files posted to Purdue data room. | 0.40 |
| 09/20/20 | JD | Finalize accounting summary and send it over to Purdue | 0.80 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | management team for review. | |
| 09/21/20 | JD | Discussion with A. DePalma and J. DelConte (both AlixPartners) re: open diligence items. | 0.20 |
| 09/21/20 | JD | Call with J. Lowne, E. Ruiz, S. Daniel (all Purdue), J. DelConte and A. DePalma (both AlixPartners) re: contract review status. | 0.50 |
| 09/21/20 | JD | Call with J. Lowne and C. DeStefano (both Purdue) re: bonus accounting accruals. | 0.80 |
| 09/21/20 | JD | Prepare for call with Purdue management re: bonus accruals. | 0.40 |
| 09/21/20 | JD | Finalize Prime Clerk schedule to be posted to the dataroom. | 0.20 |
| 09/21/20 | JD | Update information to provide to the company for immigration. | 0.30 |
| 09/21/20 | JD | Correspondence with Fidelity re: pension termination estimates. | 0.20 |
| 09/21/20 | JD | Correspondence with Davis Polk and PJT re: cost of delayed bankruptcy emergence materials. | 0.50 |
| 09/21/20 | JD | Update latest professional fee actuals and forecast through Q1 2021. | 0.80 |
| 09/21/20 | JD | Assemble different attrition analyses for KEIP/KERP. | 2.60 |
| 09/21/20 | JD | Follow up correspondence with Purdue re: AG settlements and bonus clawbacks. | 0.60 |
| 09/21/20 | JD | Draft responses to UCC HRT diligence questions. | 0.40 |
| 09/21/20 | JD | Follow up and edit Nalmefene reporting for the month. | 0.30 |
| 09/21/20 | JD | Call with J. Turner (PJT) re: call follow up. | 0.20 |
| 09/21/20 | GJK | Call with I McClatchey (Norton Rose) re: general state of diligence. | 0.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/21/20 | GJK | Plan and coordinate diligence report updates. | 2.50 |
| 09/21/20 | GJK | Review Mundipharma model cases bridges. | 1.50 |
| 09/21/20 | GJK | Review Mundipharma net working capital historical and current model analysis. | 2.40 |
| 09/21/20 | NAS | Draft risk adjustment slides and supporting materials related to Mundipharma COGS, S&P, and MA cost structure. | 2.40 |
| 09/21/20 | NAS | Draft risk adjustment slides and supporting materials related to Mundipharma operational risks. | 2.20 |
| 09/21/20 | NAS | Review prior Mundipharma diligence files for additional information on inventory levels. | 0.90 |
| 09/21/20 | ADD | Discussion with A. DePalma and J. DelConte (both AlixPartners) re: open diligence items. | 0.20 |
| 09/21/20 | ADD | Call with J. Lowne, E. Ruiz, S. Daniel (all Purdue), J. DelConte and A. DePalma (both AlixPartners) re: contract review status. | 0.50 |
| 09/21/20 | KM | Develop transition team structure and approach re: project Catalyst. | 1.90 |
| 09/21/20 | KM | Edit and update transition plan for steering review re: project Catalyst. | 2.50 |
| 09/22/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning | 0.90 |
| 09/22/20 | KM | Discussion with D. Lundie (Purdue) re: project Catalyst transition. | 0.80 |
| 09/22/20 | KM | Transition tracking process design and smartsheet editing re: project catalyst. | 1.60 |
| 09/22/20 | KM | Call J. Doyle, D. Fogel, and D. Lundie, K. McCarthy, R. Aleali, J. Lowne (all Purdue), A. DePalma, K. McCafferty | 1.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | (both AlixPartners) and Arnold & Porter legal team. re: Transition Planning and Legal Considerations. | |
| 09/22/20 | KM | Edit transition planning introduction re: project Catalyst. | 0.70 |
| 09/22/20 | KM | Transition planning and legal considerations re: project Catalyst. | 1.10 |
| 09/22/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning | 0.90 |
| 09/22/20 | ADD | Call J. Doyle, D. Fogel, and D. Lundie, K. McCarthy, R. Aleali, J. Lowne (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) and Arnold & Porter legal team. re: Transition Planning and Legal Considerations. | 1.00 |
| 09/22/20 | ADD | Download and organize data for liquidation analysis. | 1.80 |
| 09/22/20 | HSB | Review UST objection to KEIP/KERP in preparation for meeting with Davis Polk team. | 0.60 |
| 09/22/20 | HSB | Review AHC memo (KEIP/KERP) in preparation for meeting with Davis Polk team. | 0.80 |
| 09/22/20 | NAS | Draft new Mundipharma diligence report slides related to product-level risk adjustments. | 2.90 |
| 09/22/20 | NAS | Correspondence with J. Arsic (PJT) re: analysis of Mundipharma free cash flow by product category. | 0.50 |
| 09/22/20 | NAS | Draft new Mundipharma diligence report slides related to region-level cost reduction adjustments. | 2.00 |
| 09/22/20 | GJK | Review key findings slides for report updates. | 1.90 |
| 09/22/20 | GJK | Assess COS and Opex ratios between model cases. | 2.50 |
| 09/22/20 | SKL | Review and reconcile August Business Plan deck and began redaction process for non-PEO report. | 2.40 |
| 09/22/20 | SKL | Finalize redaction of the non-PEO August business plan update. | 1.20 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/22/20 | JD | Call with R. Kreppel (Purdue) re: AG settlements. | 0.50 |
| 09/22/20 | JD | Call with J. Lowne (Purdue), J. Turner, T. Melvin (both PJT) re: business plan sensitivities. | 0.50 |
| 09/22/20 | JD | Review business plan overview deck to create a non-PEO version. | 0.50 |
| 09/22/20 | JD | Correspondence with Davis Polk re: AHC feedback on the KEIP/KERP. | 0.40 |
| 09/22/20 | JD | Correspondence with management and Davis Polk re: AIP calculations. | 0.30 |
| 09/22/20 | JD | Correspondence with R. Aleali (Purdue) and C. Oluwole (Davis Polk) re: AHC request to share certain wage information. | 0.60 |
| 09/22/20 | JD | Create list of employees per UCC proposal for Skadden. | 0.70 |
| 09/22/20 | JD | Review professional fee budget template for 2021 budgeting. Work on preliminary budget estimates. | 1.30 |
| 09/22/20 | JD | Correspondence with management and Davis Polk re: Nalmafene reporting. | 0.30 |
| 09/22/20 | JD | Finalize attrition numbers and send around to Davis Polk. | 2.00 |
| 09/22/20 | JD | Review updated term list for latest attrition details. | 0.30 |
| 09/22/20 | JD | Review Side A net asset report. | 0.70 |
| 09/22/20 | JD | Review latest comments to the latest transition plan. | 0.30 |
| 09/23/20 | JD | Call with D. Consla, E. Vonnegut, S. Brecher (all Davis Polk), J. Gartrell, S. Hinden (Willis Towers Watson), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP hearing status call. | 0.50 |
| 09/23/20 | JD | Call with J. McClammy, C. Oluwole (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: Landau deposition prep. | 0.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/23/20 | JD | Begin preparing analysis of historical LTRP grant amounts by year by level by company. | 1.70 |
| 09/23/20 | JD | Review latest weekly sales report by product for Rhodes and Purdue. Analyze latest sales trends. | 0.60 |
| 09/23/20 | JD | Review bonus repayment tracker and compare it to the latest wage file. | 0.80 |
| 09/23/20 | JD | Review retention detail sheet and repayment obligations. | 0.40 |
| 09/23/20 | JD | Review mediators report that was filed. | 0.40 |
| 09/23/20 | JD | Review attrition survey stats from Willis Towers Watson. | 0.20 |
| 09/23/20 | JD | Review detailed Project Catalyst savings file. | 0.50 |
| 09/23/20 | JD | Review notes from Purdue and Davis Polk re: go forward compensation planning. | 0.30 |
| 09/23/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to review draft of Mundipharma risk adjustment slides. | 1.20 |
| 09/23/20 | SKL | Prepare for and attend call with D. Consla, E. Vonnegut, S. Brecher (all Davis Polk), J. Gartrell, S. Hinden (Willis Towers Watson), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP hearing status call. | 0.60 |
| 09/23/20 | SKL | Call with J. McClammy, C. Oluwole (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: Landau deposition prep. | 0.30 |
| 09/23/20 | SKL | Finalize latest Purdue weekly sales by product report and circulate for production. | 1.20 |
| 09/23/20 | SKL | Finalize latest Rhodes weekly sales by product report and circulate for production. | 1.00 |
| 09/23/20 | GJK | Prepare and review for risk adjustment discussion. | 1.00 |
| 09/23/20 | GJK | Review Mundipharma diligence open items including LEK, DB and CFO questions. | 2.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/23/20 | GJK | Develop edits to Mundipharma overview slides. | 2.00 |
| 09/23/20 | NAS | Review latest draft of Mundipharma risk adjustment slides. | 1.70 |
| 09/23/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to review draft of Mundipharma risk adjustment slides. | 1.20 |
| 09/23/20 | NAS | Revise Mundipharma risk adjustment slides following comments from G. Koch (AlixPartners). | 2.90 |
| 09/23/20 | HSB | Call with D. Consla, E. Vonnegut, S. Brecher (all Davis Polk), J. Gartrell, S. Hinden (Willis Towers Watson), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP hearing status call. | 0.50 |
| 09/23/20 | HSB | Call with J. McClammy, C. Oluwole (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: Landau deposition prep. | 0.30 |
| 09/23/20 | ADD | Call J. Giordano (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Post-signing contract management discussion | 0.50 |
| 09/23/20 | ADD | Call with J. McClammy, C. Oluwole (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: Landau deposition prep. | 0.30 |
| 09/23/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning presentation review. | 0.80 |
| 09/23/20 | ADD | Meeting with D. Lundie, R. Shamblen, V. Mancinelli, J. Doyle, D. McGuire, J. Northington, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: business integration planning for Catalyst. | 1.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/23/20 | ADD | Call E. Ruta (Purdue), K. McCafferty, A. DePalma (AlixPartners) re Post-signing contract management discussion | 0.40 |
| 09/23/20 | KM | Call E. Ruta (Purdue), K. McCafferty, A. DePalma (AlixPartners) re Post-signing contract management discussion | 0.40 |
| 09/23/20 | KM | Analysis re: contract information and reporting requirements. | 0.50 |
| 09/23/20 | KM | Call J. Giordano (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Post-signing contract management discussion | 0.50 |
| 09/23/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning presentation review. | 0.80 |
| 09/23/20 | KM | PMO process management re: project Catalyst needs and requirements. | 1.40 |
| 09/23/20 | KM | Meeting with D. Lundie, R. Shamblen, V. Mancinelli, J. Doyle, D. McGuire, J. Northington, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: business integration planning for Catalyst. | 1.00 |
| 09/23/20 | KM | Follow up with Rhodes Tech re: operations and supply chain analyses for Catalyst. | 1.00 |
| 09/23/20 | KM | Update transition plan for Leadership launch re: project Catalyst. | 0.40 |
| 09/24/20 | KM | Create preliminary tracking report re: Catalyst implementation. | 0.70 |
| 09/24/20 | KM | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition planning. | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/24/20 | KM | Analysis and document editing re: transition PMO for Catalyst. | 1.70 |
| 09/24/20 | KM | Create transition team onboarding materials re: project Catalyst transition. | 1.50 |
| 09/24/20 | KM | Meeting with J. Giordano, D. McGuire, J. Northington (Purdue) re: Catalyst transition planning for Wilson NC. | 0.40 |
| 09/24/20 | KM | Analysis re: contracts for Catalyst. | 0.90 |
| 09/24/20 | KM | Meeting with J. Giordano (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition PMO planning. | 0.60 |
| 09/24/20 | KM | Create documents for Kickoff re: Catalyst transition planning. | 1.30 |
| 09/24/20 | ADD | Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition planning. | 0.60 |
| 09/24/20 | ADD | Meeting with J. Giordano (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition PMO planning. | 0.60 |
| 09/24/20 | ADD | Call with C. Oluwole, J. McClammy (both Davis Polk), J. Turner, T. Melvin (both PJT), L. Imes, C. Dysard (both Spears Imes), J. DelConte and A. DePalma (both AlixPartners) re: Landau deposition. | 0.40 |
| 09/24/20 | HSB | Call with D. Consla, E. Vonnegut, S. Brecher (Davis Polk), S. Hinden (Willis Towers Watson), H. Bhattal, J. DelConte, S. Lemack (all AlixPartners) re: KEIP/KERP responses. | 0.50 |
| 09/24/20 | NAS | Review revisions to Mundipharma risk adjustment diligence report slides. | 0.20 |
| 09/24/20 | GJK | Frame out new findings pages for Mundipharma report update. | 2.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/24/20 | GJK | Review Mundipharma documents for support for revised key findings. | 3.00 |
| 09/24/20 | SKL | Prepare for and participate in call with D. Consla, E. Vonnegut, S. Brecher (Davis Polk), S. Hinden (Willis Towers Watson), H. Bhattal, J. DelConte, S. Lemack (all AlixPartners) re: KEIP/KERP responses. | 0.60 |
| 09/24/20 | JD | Correspondence with Davis Polk and management re: response to KEIP/KERP proposals. | 0.80 |
| 09/24/20 | JD | Review presentations sent around for C. Landau (Purdue) deposition prep. | 0.50 |
| 09/24/20 | JD | Correspondence with Purdue re: HRT diligence questions. | 0.30 |
| 09/24/20 | JD | Call with D. Consla, E. Vonnegut, S. Brecher (Davis Polk), S. Hinden (Willis Towers Watson), H. Bhattal, J. DelConte, S. Lemack (all AlixPartners) re: KEIP/KERP responses. | 0.50 |
| 09/24/20 | JD | Call with C. Oluwole, J. McClammy (both Davis Polk), J. Turner, T. Melvin (both PJT), L. Imes, C. Dysard (both Spears Imes), J. DelConte and A. DePalma (both AlixPartners) re: Landau deposition. | 0.40 |
| 09/25/20 | JD | Participate in PPI Board meeting, J. DelConte, L. Donahue (both AlixPartners) in attendance | 3.50 |
| 09/25/20 | JD | Review materials in advance of board meeting. | 0.70 |
| 09/25/20 | JD | Participate in call with S. Hinden, J. Gartrell (both Willis Towers Watson), D. Consla, S. Brecher (both Davis Polk), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP responses. | 0.50 |
| 09/25/20 | JD | Call with S. Hinden and J. Gartrell (both Willis Towers Watson) re: KEIP/KERP reductions. | 0.30 |
| 09/25/20 | JD | Prepare summary schedule of reductions by group in the KEIP/KERP motion. | 1.40 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/25/20 | JD | Prepare revised version of the summary KEIP/KERP reduction schedule after discussion with Willis Towers Watson. | 1.80 |
| 09/25/20 | LJD | Participate in PPI Board meeting, J. DelConte, L. Donahue (both AlixPartners) in attendance | 3.50 |
| 09/25/20 | SKL | Participate in call with S. Hinden, J. Gartrell (both Willis Towers Watson), D. Consla, S. Brecher (both Davis Polk), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP responses. | 0.50 |
| 09/25/20 | GJK | Review latest Mundipharma modeling. | 2.50 |
| 09/25/20 | GJK | Plan and coordinate upcoming calls and completion of draft final report. | 2.90 |
| 09/25/20 | NAS | Revise risk adjustment section of draft Mundipharma diligence report. | 2.90 |
| 09/25/20 | HSB | Participate in call with S. Hinden, J. Gartrell (both Willis Towers Watson), D. Consla, S. Brecher (both Davis Polk), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP responses. | 0.50 |
| 09/25/20 | ADD | Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update. | 0.20 |
| 09/25/20 | ADD | Upload materials provided by Davis Polk's eDiscovery team to the Intralinks data room. | 2.30 |
| 09/25/20 | ADD | Meeting with E. Ruta, K. McCarthy (both Purdue), A. Gallogly, M. Gibson (both Skadden) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst continuing contract review. | 0.50 |
| 09/25/20 | KM | Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update. | 0.20 |
| 09/25/20 | KM | Call with D. Lundie (Purdue) re: Catalyst transition and Rhodes Pharma going forward. | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/25/20 | KM | Process tracking and development re: project Catalyst. | 0.80 |
| 09/25/20 | KM | Transition milestone update re: project Catalyst. | 1.80 |
| 09/25/20 | KM | Meeting with E. Ruta, K. McCarthy (both Purdue), A. Gallogly, M. Gibson (both Skadden) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst continuing contract review. | 0.50 |
| 09/25/20 | KM | Milestone tracking development re: Catalyst transition planning. | 1.40 |
| 09/26/20 | JD | Correspondence with Willis Towers Watson and Davis Polk re: KEIP/KERP reductions. | 0.30 |
| 09/26/20 | JD | Prepare final KEIP/KERP analysis and provide responses to the UCC. | 0.80 |
| 09/27/20 | JD | Correspondence with management and Davis Polk re: proposals from the UCC on the KEIP/KERP. | 0.80 |
| 09/27/20 | JD | Prepare summary response for KEIP/KERP negotiations including analysis of business performance to date and other qualitative reasons for the necessity of the compensation programs. | 1.30 |
| 09/28/20 | JD | Call with J. Lowne, J. Doyle, D. Fogel (all Purdue), J. Turner, T. Melvin (both PJT) re: potential BD deals. | 0.30 |
| 09/28/20 | JD | Call with J. DelConte and K. McCafferty (both AlixPartners) re: transition planning. | 0.50 |
| 09/28/20 | JD | Correspondence with Davis Polk re: discussions with Bates White. | 0.30 |
| 09/28/20 | JD | Review and provide comments on the draft non-PEO version of the August refresh business plan presentation to share with various creditors. | 1.80 |
| 09/28/20 | JD | Review and provide comments on the debtor KEIP/KERP objection reply. | 0.90 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/28/20 | JD | Review Rhodes BD deal opportunity presentation. | 0.30 |
| 09/28/20 | JD | Review revised August business plan refresh files to be posted to the data room for the creditor advisors. | 0.40 |
| 09/28/20 | NAS | Revise risk adjustment section of Mundipharma diligence report following comments from G. Koch (AlixPartners). | 1.20 |
| 09/28/20 | NAS | Draft qualitative risk factor slides for Mundipharma diligence report. | 1.40 |
| 09/28/20 | NAS | Draft Downside Case risk adjustment slides for Mundipharma diligence report. | 1.20 |
| 09/28/20 | NAS | Update latest draft of Mundipharma diligence report with latest Base Case. | 0.90 |
| 09/28/20 | SKL | Review the April non-PEO business plan and continue to make updates to the non-PEO August business plan refresh. | 2.40 |
| 09/28/20 | SKL | Continue to finalize redactions to the August business plan refresh and circulate for final sign-off. | 1.50 |
| 09/28/20 | KM | Call with J. DelConte and K. McCafferty (both AlixPartners) re: transition planning. | 0.50 |
| 09/28/20 | KM | Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update. | 0.60 |
| 09/28/20 | KM | Link milestone tracking re: project Catalyst. | 0.50 |
| 09/28/20 | KM | Meeting with V. Mancinelli, R. Shamblen, A. Nadeau, J. Gibbs, E. Ruta (Purdue), D. McGuire, B. Evans, J. Giordano (Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - supply chain kickoff. | 1.20 |
| 09/28/20 | KM | Preliminary milestone identification re: Catalyst core supply chain and procurement activities. | 1.10 |
| 09/28/20 | KM | Preliminary milestone identification re: Catalyst tech transfers. | 1.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/28/20 | KM | Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Eber, J. Waltz, B. Mayer, K. Kolar, A. Soma, A. Nadeau, J. Doyle, E. Ruta, D. Shell, J. Gibbs, S. Yates, D. McGuire, J. Northington, J. Fox, D. Eades, B. Evans, S. Aschmann, B. Purdon, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - kick off and orientation - Operations, Tech Transfers, Supply Chain, Quality / Regulatory | 0.60 |
| 09/28/20 | KM | Call with J. Giordano (Purdue) re: Catalyst transition kickoff. | 0.30 |
| 09/28/20 | KM | Workstream edits and improvements re: project Catalyst transition kickoff. | 1.50 |
| 09/28/20 | KM | Prepare documents re: project Catalyst transition kickoff. | 2.20 |
| 09/28/20 | ADD | Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Eber, J. Waltz, B. Mayer, K. Kolar, A. Soma, A. Nadeau, J. Doyle, E. Ruta, D. Shell, J. Gibbs, S. Yates, D. McGuire, J. Northington, J. Fox, D. Eades, B. Evans, S. Aschmann, B. Purdon, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - kick off and orientation - Operations, Tech Transfers, Supply Chain, Quality / Regulatory | 0.60 |
| 09/28/20 | ADD | Meeting with V. Mancinelli, R. Shamblen, A. Nadeau, J. Gibbs, E. Ruta (Purdue), D. McGuire, B. Evans, J. Giordano (Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - supply chain kickoff. | 1.20 |
| 09/28/20 | ADD | Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update. | 0.60 |
| 09/29/20 | ADD | Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Eber, J. Waltz, B. Mayer, K. Kolar, D. McGuire, J. Fox, D. Eades, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - | 1.10 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | tech transfers and qualifications. | |
| 09/29/20 | ADD | Meeting with V. Mancinelli, R. Shamblen, A. Soma, A. Nadeau, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Coventry operations. | 1.10 |
| 09/29/20 | ADD | Call with A. DePalma, K. McCafferty, J. DelConte (all AlixPartners) and D. Fogel (Purdue) re: material contract analysis and Project Catalyst savings. | 0.80 |
| 09/29/20 | ADD | Review material Rhodes Pharma relationships to identify material contracts for additional review and analysis. | 1.60 |
| 09/29/20 | KM | Milestone tracking approach and technology management re: project Catalyst transition. | 2.10 |
| 09/29/20 | KM | Transition PMO management re: project Catalyst transition. | 2.10 |
| 09/29/20 | KM | Call with A. DePalma, K. McCafferty, J. DelConte (all AlixPartners) and D. Fogel (Purdue) re: material contract analysis and Project Catalyst savings. | 0.80 |
| 09/29/20 | KM | Meeting with V. Mancinelli, R. Shamblen, A. Soma, A. Nadeau, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Coventry operations. | 1.10 |
| 09/29/20 | KM | Prepare for Coventry operations transition workstream launch meeting re: project Catalyst transition. | 0.10 |
| 09/29/20 | KM | Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Eber, J. Waltz, B. Mayer, K. Kolar, D. McGuire, J. Fox, D. Eades, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - tech transfers and qualifications. | 1.10 |
| 09/29/20 | KM | Prepare for transition workstream launch meetings re: project Catalyst transition. | 1.40 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/29/20 | SKL | Review latest inquiry re: PBGC termination claim and prepare updated breakdown accordingly. | 0.60 |
| 09/29/20 | SKL | Finalize remaining redactions to the August business plan refresh based on the feedback provided, and circulated updated deck and list of changes to T. Melvin (PJT) to review and sign-off. | 2.30 |
| 09/29/20 | NAS | Analyze new product-level support for September Model provided by Huron/Mundipharma. | 1.30 |
| 09/29/20 | NAS | Call with G. Koch, N. Simon (both AlixPartners) to review risk adjustment slides | 1.20 |
| 09/29/20 | NAS | Revisions to latest draft of Mundipharma diligence report following comments from G. Koch (AlixPartners). | 3.20 |
| 09/29/20 | GJK | Call with G. Koch and J. DelConte (both AlixPartners) re: IAC update. | 0.20 |
| 09/29/20 | GJK | Call with G. Koch, N. Simon (both AlixPartners) to review risk adjustment slides | 1.20 |
| 09/29/20 | GJK | Review risk adjustment slide updates and prep for call with N Simon (AlixPartners) | 0.40 |
| 09/29/20 | GJK | Develop Mundipharma diligence final report notes. | 2.00 |
| 09/29/20 | GJK | Assess Mundipharma diligence items - LAM region. | 2.10 |
| 09/29/20 | JD | Call with J. Lowne (Purdue) re: open items. | 0.20 |
| 09/29/20 | JD | Call with A. DePalma, K. McCafferty, J. DelConte (all AlixPartners) and D. Fogel (Purdue) re: material contract analysis and Project Catalyst savings. | 0.80 |
| 09/29/20 | JD | Call with J. Lowne, E. Ruiz and S. Daniel (all Purdue) re: material contract analysis. | 0.40 |
| 09/29/20 | JD | Call with G. Koch and J. DelConte (both AlixPartners) re: IAC update. | 0.20 |
| 09/29/20 | JD | Prepare quick reference sheets for the hearing on the | 2.20 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | KERP for Davis Polk outlining the top 41 paid employees. | |
| 09/29/20 | JD | Correspondence with management re: contract cure costs for a Rhodes Tech vendor. | 0.30 |
| 09/29/20 | JD | Correspondence with Fidelity and with H. Bhattal (AlixPartners) re: pension claim calculations. | 0.40 |
| 09/29/20 | JD | Call with J. Turner (PJT), E. Vonnegut, C. Robertson (Davis Polk) re: BD deals. | 0.20 |
| 09/29/20 | JD | Prepare analysis of the KERP less the 8 employee deferred employees for potential negotiations. | 0.50 |
| 09/29/20 | JD | Review bonus accrual accounting file from management. | 0.60 |
| 09/30/20 | JD | Finalize updated professional fee forecast for the remainder of 2020 and 2021 for DPW and PJT review. | 0.80 |
| 09/30/20 | JD | Call with J. Lowne (Purdue) re: prep for court hearing. | 0.20 |
| 09/30/20 | JD | Call with J. Turner (PJT) re: OxyContin sensitivities. | 0.20 |
| 09/30/20 | JD | Prepare update of bonus accrual accounting file re: with management on Friday. | 1.80 |
| 09/30/20 | GJK | Review Appendix slides for updates. | 2.00 |
| 09/30/20 | GJK | Review overview materials for updates. | 2.00 |
| 09/30/20 | NAS | Review list of Mundipharma diligence questions for 10/12 call with Deutsche Bank. | 0.70 |
| 09/30/20 | KM | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne, D. McGuire (all Purdue), M. Gibson, A. Gallogly, R. Schlossberg (all Skadden), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst closing checklist. | 1.10 |
| 09/30/20 | KM | Tracking dashboard edits re: project Catalyst. | 0.80 |
| 09/30/20 | KM | Activity tracking and transition planning re: RP and Wilson supply chain. | 2.10 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|----------------------|
| 09/30/20 | KM | Meeting with J. Giordano (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition PMO planning. | 0.50 |
| 09/30/20 | KM | Update Coventry operations transition planning re: project Catalyst. | 1.20 |
| 09/30/20 | KM | Update/edit supply chain transition planning re: project Catalyst. | 1.30 |
| 09/30/20 | KM | Edit, update and circulate tech transfer mapping re: project Catalyst transfer requirements. | 1.30 |
| 09/30/20 | ADD | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne, D. McGuire (all Purdue), M. Gibson, A. Gallogly, R. Schlossberg (all Skadden), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst closing checklist. | 1.10 |
| 09/30/20 | ADD | Meeting with J. Giordano (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition PMO planning. | 0.50 |
| Total | | | <u>623.30</u> |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|---------------|----------|-------------------|
| Andrew D DePalma | 73.50 | 515.00 | 37,852.50 |
| Sam K Lemack | 16.70 | 515.00 | 8,600.50 |
| Nate A Simon | 87.40 | 515.00 | 45,011.00 |
| Isabel Arana de Uriarte | 2.50 | 690.00 | 1,725.00 |
| Ryan D Sublett | 0.50 | 735.00 | 367.50 |
| Gabe J Koch | 108.90 | 840.00 | 91,476.00 |
| HS Bhattal | 3.60 | 840.00 | 3,024.00 |
| Kevin M McCafferty | 197.40 | 950.00 | 187,530.00 |
| Jesse DelConte | 124.40 | 950.00 | 118,180.00 |
| Lisa Donahue | 8.40 | 1,195.00 | 10,038.00 |
| Total Hours & Fees | 623.30 | | 503,804.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: POR Development
Client/Matter # 012589.00107

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/01/20 | HSB | Review PJT's valuation of Purdue and conducted related research for liquidation analysis. | 1.30 |
| 09/03/20 | HSB | Review liquidation analysis comments. | 0.40 |
| 09/03/20 | HSB | Review updated excel file with draft of liquidation analysis. | 0.80 |
| 09/03/20 | HSB | Review disclosure statements for recent pharma b/k filings for liquidation analysis assumptions. | 1.70 |
| 09/03/20 | JD | Review and provide comments on the draft liquidation analysis. Review previous liquidation analyses for context. | 2.60 |
| 09/03/20 | JD | Correspondence with Davis Polk re: plan confirmation issues. | 0.30 |
| 09/04/20 | HSB | Review draft of liquidation analysis and prepared comments for updates. | 1.30 |
| 09/08/20 | HSB | Meeting with H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to review and discuss liquidation analysis. | 0.90 |
| 09/08/20 | ADD | Meeting with H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to review and discuss liquidation analysis. | 0.90 |
| 09/08/20 | SKL | Meeting with H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to review and discuss liquidation analysis. | 0.90 |
| 09/09/20 | SKL | Continue review of latest feedback and comments received re: liquidation analysis and prepared updated assumptions accordingly. | 2.10 |
| 09/09/20 | HSB | Review recent liquidation analysis comps and related issues. | 1.20 |
| 09/09/20 | HSB | Review updated liquidation analysis and prepare comments ahead of working session. | 0.70 |
| 09/10/20 | HSB | Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) follow up meeting to review latest updates | 1.20 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: POR Development
Client/Matter # 012589.00107

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/10/20 | HSB | made to the liquidation analysis and discuss next steps. Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) initial meeting to review latest updates made to the liquidation analysis and discuss next steps. | 1.10 |
| 09/10/20 | HSB | Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) final meeting to review latest updates made to the liquidation analysis and discuss next steps. | 3.20 |
| 09/10/20 | ADD | Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) final meeting to review latest updates made to the liquidation analysis and discuss next steps. | 3.20 |
| 09/10/20 | ADD | Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) initial meeting to review latest updates made to the liquidation analysis and discuss next steps. | 1.10 |
| 09/10/20 | ADD | Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) follow up meeting to review latest updates made to the liquidation analysis and discuss next steps. | 1.20 |
| 09/10/20 | SKL | Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) follow up meeting to review latest updates made to the liquidation analysis and discuss next steps. | 1.20 |
| 09/10/20 | SKL | Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) initial meeting to review latest updates made to the liquidation analysis and discuss next steps. | 1.10 |
| 09/10/20 | SKL | Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) final meeting to review latest updates made to the liquidation analysis and discuss next steps. | 3.20 |
| 09/10/20 | SKL | Continue to work through the latest feedback received on the liquidation analysis and prepare update and breakdown for internal review. | 2.50 |
| 09/10/20 | JD | Review latest liquidation analysis edits and open questions. | 0.80 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: POR Development
Client/Matter # 012589.00107

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/14/20 | SKL | Update inventory and PPE sections of the liquidation analysis and flow through to the consolidated level. | 2.10 |
| 09/14/20 | SKL | Update liquidation analysis with asset and claim level checks on both the consolidated level and debtor by debtor level. | 1.80 |
| 09/14/20 | SKL | Continue to update the liquidation analysis with the latest postpetition AP detail and begin preparing the administrative claim portion of the analysis. | 1.40 |
| 09/15/20 | SKL | Incorporate the latest accrued rebate detail into the administrative claim component of the liquidation analysis. | 1.40 |
| 09/15/20 | HSB | Review recent pharma bankruptcy disclosure statements and related assumptions for liquidation analysis and prepare excel summary worksheet. | 2.10 |
| 09/16/20 | HSB | Meeting with J. DelConte, HS Bhattal, A. DePalma (all AlixPartners) re: latest liquidation analysis and discuss next steps. | 0.70 |
| 09/16/20 | HSB | Review Noramco APA and assessed impact on liquidation analysis. | 1.30 |
| 09/16/20 | ADD | Meeting with J. DelConte, HS Bhattal, A. DePalma (all AlixPartners) re: latest liquidation analysis and discuss next steps. | 0.70 |
| 09/16/20 | SKL | Meeting with J. DelConte, HS Bhattal, A. DePalma (all AlixPartners) re: latest liquidation analysis and discuss next steps. | 0.70 |
| 09/16/20 | JD | Meeting with J. DelConte, HS Bhattal, A. DePalma (all AlixPartners) re: latest liquidation analysis and discuss next steps. | 0.70 |
| 09/17/20 | SKL | Update the consolidated piece of the liquidation analysis with the new assumptions for PPLP, Rhodes and Avrio. | 2.10 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: POR Development
Client/Matter # 012589.00107

| Date | Consultant | Description of Services | Hours |
|--------------|------------|---|--------------|
| 09/17/20 | SKL | Finalize updates to the PPE and accrued rebate section of the latest liquidation analysis. | 1.40 |
| 09/21/20 | SKL | Meeting with A. DePalma and S. Lemak (both AlixPartners) to pull Rhodes balance sheet detail and discuss updates to the liquidation analysis accordingly. | 0.70 |
| 09/21/20 | SKL | Continue review of latest balance sheet detail provided and begin updating the liquidation analysis accordingly. | 2.30 |
| 09/21/20 | SKL | Review latest feedback provided on the Rhodes balance sheet detail and continue updating the debtor entity and consolidated tabs accordingly. | 2.60 |
| 09/21/20 | ADD | Meeting with A. DePalma and S. Lemak (both AlixPartners) to pull Rhodes balance sheet detail and discuss updates to the liquidation analysis accordingly. | 0.70 |
| 09/21/20 | HSB | Review excel draft of liquidation analysis. | 0.40 |
| 09/23/20 | ADD | Call with A. DePalma and S. Lemak (AlixPartners) re: liquidation analysis follow up items. | 0.30 |
| 09/23/20 | SKL | Call with A. DePalma and S. Lemak (AlixPartners) re: liquidation analysis follow up items. | 0.30 |
| 09/23/20 | SKL | Continue to update the liquidation analysis with the latest Rhodes balance sheet detail and claims estimates. | 2.20 |
| 09/28/20 | SKL | Meeting with A. DePalma, S. Lemack (both AlixPartners) re: liquidation analysis and follow-up items. | 0.40 |
| 09/28/20 | ADD | Meeting with A. DePalma, S. Lemack (both AlixPartners) re: liquidation analysis and follow-up items. | 0.40 |
| Total | | | 61.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: POR Development
Client/Matter # 012589.00107

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|--------------|--------|------------------|
| Andrew D DePalma | 8.50 | 515.00 | 4,377.50 |
| Sam K Lemack | 30.40 | 515.00 | 15,656.00 |
| HS Bhattal | 18.30 | 840.00 | 15,372.00 |
| Jesse DelConte | 4.40 | 950.00 | 4,180.00 |
| Total Hours & Fees | 61.60 | | 39,585.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Claims Process
Client/Matter # 012589.00109

| Date | Consultant | Description of Services | Hours |
|--------------|------------|---|-------------|
| 09/24/20 | SKL | Update claims database with the latest Prime Clerk claims report and circulate Rhodes Tech claims for review. | 1.10 |
| Total | | | 1.10 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Claims Process
Client/Matter # 012589.00109

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|-------------|--------|---------------|
| Sam K Lemack | 1.10 | 515.00 | 566.50 |
| Total Hours & Fees | 1.10 | | 566.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Special Projects
Client/Matter # 012589.00110

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/01/20 | KG | Stage and process data for loading. Perform quality control review of processed data. Export and import data into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation. | 0.80 |
| 09/01/20 | ADD | Request approval from external counsel and internal counsel to upload documents to the data room and release to external parties. | 0.60 |
| 09/01/20 | ADD | Redact documents in preparation for upload to the Project Catalyst data room. | 1.80 |
| 09/01/20 | ADD | Review Research Purdue IAC agreement list to determine if the list is incomplete. | 0.70 |
| 09/01/20 | ADD | Compile agreements for Project Catalyst's external counsel's review. | 1.20 |
| 09/01/20 | ADD | Compile and upload materials submitted in response diligence requests for upload to the Project Catalyst data room. | 2.20 |
| 09/01/20 | ADD | Review material contracts list and compile newly executed agreements for upload to the Project Catalyst data room. | 1.20 |
| 09/02/20 | ADD | Research and compile agreements for external legal review. | 2.90 |
| 09/02/20 | ADD | Compile and upload materials submitted in response diligence requests for upload to the Project Catalyst data room. | 2.80 |
| 09/02/20 | ADD | Work with external legal counsel to identify agreements to share in the Project Catalyst data room. | 1.20 |
| 09/02/20 | ADD | Request approval from external counsel and internal counsel to upload documents to the data room and | 0.80 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Special Projects
Client/Matter # 012589.00110

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | release to external parties. | |
| 09/02/20 | ADD | Review consent requirements to share agreements with third parties for project catalyst. | 0.50 |
| 09/03/20 | ADD | Research and analyze Rhodes Tech contractual relationships to assist external counsel with schedule creation. | 2.80 |
| 09/03/20 | ADD | Compile and upload documents submitted in response to diligence request for upload to the data room. | 2.60 |
| 09/03/20 | ADD | Request approval from external counsel and internal counsel to upload documents to the data room and release to external parties. | 1.20 |
| 09/04/20 | ADD | Compile and agreements in response to Project Catalyst diligence request and request approval to upload. | 2.30 |
| 09/06/20 | ADD | Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle (Purdue), K. McCarthy, R. Aleali, J. Lowne (Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: MSA review. | 3.30 |
| 09/08/20 | ADD | Compile data and update cure cost calculation to determine entities with prepetition liabilities. | 3.10 |
| 09/14/20 | ADD | Research possible addresses for noticing purposes for Rhodes Tech counter parties with missing contact information. | 0.80 |
| 09/14/20 | ADD | Review and analysis of Rhodes Tech contracts for project catalyst term sheet schedules. | 2.40 |
| 09/14/20 | ADD | Research and compile noticing addresses to notify Rhodes Tech counter parties re: project catalyst. | 3.30 |
| 09/14/20 | ADD | Compile and upload documents responsive to diligence request to the Project Catalyst data room. | 1.80 |
| 09/15/20 | ADD | Prepare and upload ad hoc committee diligence requests | 1.90 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Special Projects
Client/Matter # 012589.00110

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | to the data room for review by the committees. | |
| 09/15/20 | ADD | Research possible addresses for noticing purposes for Rhodes Tech counter parties with missing contact information. | 0.50 |
| 09/16/20 | ADD | Review and analyze Rhodes contracts for materiality and relative importance. | 1.00 |
| 09/16/20 | ADD | Research Rhodes' counter party addresses for noticing purposes. | 1.40 |
| 09/17/20 | ADD | Compile materials submitted in response to diligence requests in preparation for processing and upload to the data room | 1.80 |
| 09/17/20 | ADD | Call with D. Fogel (Purdue) and A. DePalma., K. McCafferty (AlixPartners) re: RP contract analysis results. | 0.90 |
| 09/17/20 | ADD | Research Rhodes' counter party addresses for noticing purposes. | 1.60 |
| 09/18/20 | ADD | Research Rhodes' counter party addresses for noticing purposes. | 0.60 |
| 09/18/20 | ADD | Draft correspondence to follow up on outstanding diligence requests. | 0.50 |
| 09/18/20 | KG | Coordinate with ETS to reactivate Relativity credentials for S. Canniff (AlixPartners). | 0.10 |
| 09/21/20 | ADD | Research Rhodes' counter party addresses for noticing purposes. | 0.70 |
| 09/22/20 | KG | Stage and import third party productions into Relativity. Troubleshoot load file issues and import errors into Relativity. | 3.30 |
| 09/23/20 | KG | Export and create copies of documents as requested by A. DePalma (AlixPartners). Perform quality control review of new data. Generate TIF images. | 1.80 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Special Projects
Client/Matter # 012589.00110

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|--------------|
| 09/25/20 | KG | Run Blackout process across requested documents. Batch documents that need review. | 1.20 |
| 09/25/20 | ADD | Review and compile Rhodes agreements to update contract database for Project Catalyst. | 1.90 |
| 09/27/20 | ADD | Review Purdue employment data and prepare information requested by Davis Polk. | 2.40 |
| 09/30/20 | ADD | Compile and review Rhodes Technologies contracts in preparation for closing. | 3.20 |
| 09/30/20 | ADD | Review agreements shared with Rhodes Tech bidders and identify additional agreements to be shared via the data room. | 1.40 |
| Total | | | 66.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|--------------|--------|------------------|
| Andrew D DePalma | 59.30 | 515.00 | 30,539.50 |
| Kristina Galbraith | 7.20 | 645.00 | 4,644.00 |
| Total Hours & Fees | 66.50 | | 35,183.50 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

| Date | Consultant | Description of Services | Hours |
|--------------|------------|--------------------------------------|-------------|
| 09/03/20 | ESK | Work on the Purdue disclosure matter | 0.30 |
| Total | | | 0.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|-------------|--------|---------------|
| Elizabeth S Kardos | 0.30 | 710.00 | 213.00 |
| Total Hours & Fees | 0.30 | | 213.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/01/20 | MSM | Prepare professional fees for August 2020 fee statement. | 0.80 |
| 09/02/20 | JD | Finalize review of draft July fee statement to file with the court. | 2.60 |
| 09/03/20 | MSM | Prepare professional fees for August 2020 fee statement. | 2.00 |
| 09/04/20 | TB | Prepare the eleventh monthly fee statement for July 2020 and exhibits. | 1.40 |
| 09/04/20 | JD | Review final mark up and final version of the July fee statement. | 0.30 |
| 09/08/20 | TB | Email to M. Pera, D. Consla, C. Robertson (all David Polk) attaching the eleventh monthly fee statement July 2020 for filing with the court. | 0.20 |
| 09/08/20 | MSM | Prepare professional fees for August 2020 fee statement. | 3.80 |
| 09/12/20 | MSM | Prepare professional fees for August 2020 fee statement. | 3.20 |
| 09/12/20 | MSM | Continue to prepare professional fees for August 2020 fee statement. | 2.80 |
| 09/13/20 | MSM | Prepare professional fees for August 2020 fee statement. | 1.20 |
| 09/13/20 | MSM | Continue to prepare professional fees for August 2020 fee statement. | 3.60 |
| 09/13/20 | MSM | Further preparation of professional fees for August 2020 fee statement. | 2.70 |
| 09/14/20 | MSM | Prepare professional fees for August 2020 fee statement. | 3.90 |
| 09/15/20 | MSM | Prepare professional fees for August 2020 fee statement. | 4.00 |
| 09/19/20 | MSM | Prepare professional fees for September 2020 fee statement. | 2.20 |
| 09/28/20 | TB | Prepare monthly fee statement and exhibits for August 2020. | 1.40 |
| 09/28/20 | JD | Start the initial review of the August fee statement to be filed with the court. | 2.20 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|--------------|
| 09/28/20 | JD | Finish review of the August fee statement to be provided to the court and provide comments for the next turn of the draft. | 2.10 |
| 09/29/20 | TB | Update of exhibit A on the August monthly fee statement. | 0.20 |
| Total | | | 40.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|--------------|--------|------------------|
| Melanie McCabe | 30.20 | 415.00 | 12,533.00 |
| Tammy Brewer | 3.20 | 450.00 | 1,440.00 |
| Jesse DelConte | 7.20 | 950.00 | 6,840.00 |
| Total Hours & Fees | 40.60 | | 20,813.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Court Hearings
Client/Matter # 012589.00114

| Date | Consultant | Description of Services | Hours |
|--------------|------------|---|-------------|
| 09/30/20 | NAS | Attend 9/30 telephonic hearing (partial). | 3.40 |
| 09/30/20 | JD | Listen in to telephonic court hearing. | 4.00 |
| 09/30/20 | HSB | Court hearing (dialed in) re: KERP. | 1.80 |
| Total | | | 9.20 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|-------------|--------|-----------------|
| Nate A Simon | 3.40 | 515.00 | 1,751.00 |
| HS Bhattal | 1.80 | 840.00 | 1,512.00 |
| Jesse DelConte | 4.00 | 950.00 | 3,800.00 |
| Total Hours & Fees | 9.20 | | 7,063.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Forensic Analysis
Client/Matter # 012589.00115

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/01/20 | SJC | 2012 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 0.40 |
| 09/01/20 | SJC | 2011 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 1.60 |
| 09/01/20 | SJC | 2010 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 3.20 |
| 09/01/20 | SJC | 2009 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 2.70 |
| 09/02/20 | SJC | 2015 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 3.60 |
| 09/02/20 | SJC | Organizing support for 2008 Rhodes/Coventry tax distributions for data room. | 2.20 |
| 09/02/20 | FOS | Compose emails to R. Collura and M. Rule (AlixPartners) re: 2019 MITS (UK) and PPLP IT Services Agreement. | 1.00 |
| 09/02/20 | SJC | Review of Rhodes/Coventry 2009 Tax Distributions and supporting documentation including funding. | 3.00 |
| 09/02/20 | RC | Review and comment on response to questions received from the UCC re: the non-cash transfers of value report. | 0.80 |
| 09/03/20 | SJC | Review of Rhodes/Coventry 2010 Tax Distributions and supporting documentation including funding. | 0.70 |
| 09/03/20 | SJC | Review of Rhodes/Coventry 2011 Tax Distributions and supporting documentation including funding. | 1.90 |
| 09/03/20 | SJC | Review of Rhodes/Coventry 2013 Tax Distributions and supporting documentation including funding. | 3.10 |
| 09/03/20 | SJC | Review of Rhodes/Coventry 2012 Tax Distributions and supporting documentation including funding. | 1.50 |
| 09/04/20 | SJC | 2012 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 1.10 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Forensic Analysis
Client/Matter # 012589.00115

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| 09/04/20 | SJC | 2017 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 0.10 |
| 09/04/20 | SJC | 2018 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 0.60 |
| 09/04/20 | SJC | 2016 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 1.00 |
| 09/04/20 | SJC | 2015 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 0.50 |
| 09/08/20 | SJC | 2015 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 1.90 |
| 09/08/20 | SJC | 2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 3.00 |
| 09/08/20 | SJC | Continue 2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 3.30 |
| 09/08/20 | REO | Review non cash transfers from PPLP to PRA re: Lucien, New Suffolk and RSJ transfers | 1.50 |
| 09/08/20 | FOS | Compose email to R. Collura and M. Rule (All AlixPartners) re: question from Province re: RSJ assignment and assumption transaction. | 1.00 |
| 09/08/20 | MFR | Review and analysis of documents related to RSJ transfer. Discussion with F. Silva (AlixPartners) re: the same and internal email re: the same. | 1.20 |
| 09/09/20 | SJC | 2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 1.70 |
| 09/09/20 | SJC | 2010 Rhodes distribution analysis and pulling documentation from SAP and bank statements. | 4.40 |
| 09/10/20 | RC | Review documentation related to responses to requests from the UCC. | 1.30 |
| 09/10/20 | RC | Review summary of information gathered in response to | 0.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Forensic Analysis
Client/Matter # 012589.00115

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| | | requests from the UCC. | |
| 09/11/20 | RC | Review and summarize information related to non-cash transfers value of report and respond to requests from Davis Polk. | 0.60 |
| 09/11/20 | RC | Review information related to tax distributions. | 0.50 |
| 09/11/20 | RC | Review support documentation related to non-tax distributions. | 1.20 |
| 09/11/20 | RC | Review information gathered in response to the UCC's requests related to the cash transfers of value report. | 1.40 |
| 09/11/20 | FOS | Compose email to R. Collura (AlixPartners) re: Davis Polk request for documents reviewed for Report 1B and hours billed. | 0.70 |
| 09/14/20 | SJC | Pull and organize support for 2009 Coventry tax distributions for data room. | 1.20 |
| 09/14/20 | SJC | Review of compensation data in response to request from DPW. | 2.30 |
| 09/14/20 | SJC | Pull and organize support for 2010 Coventry tax distributions for data room. | 1.50 |
| 09/14/20 | SJC | Pull and organize support for 2011 Coventry tax distributions for data room. | 2.20 |
| 09/14/20 | RC | Review and research information requests received from the UCC re: S. Baker. | 1.30 |
| 09/14/20 | RC | Prepare summary of compensation related requests made by the UCC's advisors. | 1.40 |
| 09/15/20 | RC | Review documents gathered in response to the UCC's requests related to the cash transfers of value report. | 0.80 |
| 09/15/20 | RC | Review source documents related to information requests made by the UCC's advisors. | 1.00 |
| 09/15/20 | SJC | Pull and organize support for 2012 Coventry tax | 1.00 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Forensic Analysis
Client/Matter # 012589.00115

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | distributions for data room. | |
| 09/15/20 | SJC | Pull and organize support for 2013 Coventry tax distributions for data room. | 1.20 |
| 09/15/20 | SJC | Pull and organize support for 2014 Coventry tax distributions for data room. | 2.50 |
| 09/15/20 | SJC | Pull and organize support for 2016 Coventry tax distributions for data room. | 1.60 |
| 09/15/20 | SJC | Pull and organize support for 2017 Coventry tax distributions for data room. | 1.00 |
| 09/16/20 | SJC | Pull and organize support for 2018 Coventry tax distributions for data room. | 0.50 |
| 09/16/20 | SJC | Pull and organize support for 2015 Coventry tax distributions for data room. | 3.00 |
| 09/16/20 | SJC | Continue to pull and organize support for 2015 Coventry tax distributions for data room. | 1.20 |
| 09/16/20 | RC | Review support documentation related to non-tax distributions in response to requests from the UCC. | 0.90 |
| 09/16/20 | RC | Review documentation gathered in response to the UCC's cash distribution requests. | 1.20 |
| 09/16/20 | ADD | Draft correspondences to request materials responsive to committee diligence requests. | 0.30 |
| 09/16/20 | ADD | Prepare distribution support documentation to send to Davis Polk for processing and upload to the data room. | 1.10 |
| 09/17/20 | ADD | Call with A. DePalma, S. Canniff (AlixPartners) re: re: Coventry/Rhodes distributions and Purdue tax support. | 1.30 |
| 09/17/20 | RC | Review information gathered in response to the UCC's requests for tax related information. | 0.40 |
| 09/17/20 | SJC | Call to with S. Canniff, A. DePalma (both AlixPartners) re: Coventry/Rhodes distributions and Purdue tax support. | 1.30 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Forensic Analysis
Client/Matter # 012589.00115

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|-------|
| 09/18/20 | SJC | Review of tax returns in Relativity. | 3.20 |
| 09/18/20 | RC | Review support documentation gathered in response to requests from Province. | 0.80 |
| 09/18/20 | RC | Review and comment on support documentation gathered in response to distribution related requests. | 1.10 |
| 09/18/20 | RC | Review of information produced by Debevoise re: distributions. | 0.50 |
| 09/18/20 | ADD | Review and categorize tax materials submitted by TXP counsel. | 2.30 |
| 09/21/20 | ADD | Review outstanding diligence requests and draft request from appropriate client contacts. | 2.10 |
| 09/21/20 | RC | Review and comment on support documentation related US and Ex-US distributions. | 1.30 |
| 09/21/20 | RC | Review information related to distributions provided by the Sackler's counsel. | 0.90 |
| 09/21/20 | RC | Review support documentation gathered in response to request from the UCC's advisors. | 1.10 |
| 09/22/20 | RC | Review support documentation gathered in response to requests from the UCC's advisors. | 1.20 |
| 09/22/20 | RC | Review US distribution support documentation. | 0.70 |
| 09/22/20 | RC | Review Ex-US distribution support documentation. | 1.30 |
| 09/23/20 | RC | Review support documentation related to Ex-US distributions. | 0.80 |
| 09/23/20 | RC | Review support documentation related to non-tax distributions. | 0.70 |
| 09/23/20 | RC | Review and comment on documents gathered in response to the UCC's requests. | 1.40 |
| 09/23/20 | FOS | Organize and prepare supporting documentation re: | 1.60 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Forensic Analysis
Client/Matter # 012589.00115

| Date | Consultant | Description of Services | Hours |
|----------|------------|---|-------|
| | | Report 1B document requests. | |
| 09/23/20 | ADD | Review tax materials submitted by TXP Services in response to committee diligence requests. | 1.80 |
| 09/24/20 | ADD | Call with A. DePalma, S. Canniff (both AlixPartners) re: Purdue tax support and Purdue tax distributions | 1.30 |
| 09/24/20 | FOS | Organize and prepare supporting documentation re: Report 1B document requests. | 3.30 |
| 09/24/20 | SJC | Call with A. DePalma, S. Canniff (both AlixPartners) re: Purdue tax support and Purdue tax distributions. | 1.30 |
| 09/24/20 | SJC | Review of support provided for Ardsley distribution and related SAP review. | 2.10 |
| 09/24/20 | RC | Review support documentation gathered in response to requests from the UCC's advisors. | 1.30 |
| 09/24/20 | RC | Review distribution information provided by the Sackler's counsel. | 0.90 |
| 09/25/20 | RC | Review and comment on documentation gathered in response to the UCC's requests. | 1.10 |
| 09/25/20 | RC | Review distribution information produced by the Sacklers. | 1.20 |
| 09/25/20 | SJC | Review and redaction of September Board Materials. | 3.80 |
| 09/25/20 | FOS | Organize and prepare supporting documentation re: Report 1B document requests. | 3.00 |
| 09/28/20 | FOS | Organize and prepare supporting documentation re: Report 1B document requests. | 1.20 |
| 09/28/20 | SJC | Continue review and redaction of September Board Materials. | 3.50 |
| 09/28/20 | SJC | Review and redaction of September Board Materials. | 3.50 |
| 09/28/20 | RC | Review documentation gathered in response to requests from the UCC's advisors. | 1.20 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Forensic Analysis
Client/Matter # 012589.00115

| Date | Consultant | Description of Services | Hours |
|----------|------------|--|---------------|
| 09/28/20 | RC | Perform additional review of the non-tax distribution support documentation | 0.80 |
| 09/29/20 | RC | Review support documentation gathered in response to the UCC's requests for non-tax distributions. | 1.30 |
| 09/29/20 | SJC | Review and redaction of September Board Materials. | 3.00 |
| 09/29/20 | SJC | Continue review and redaction of September Board Materials. | 2.00 |
| Total | | | 142.10 |

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2128738-1

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

| Consultant | Hours | Rate | Amount |
|-------------------------------|---------------|----------|-------------------|
| Roy Ellis Ochoa | 1.50 | 420.00 | 630.00 |
| Andrew D DePalma | 10.20 | 515.00 | 5,253.00 |
| Sam J Canniff | 84.40 | 645.00 | 54,438.00 |
| Fernando O Silva | 11.80 | 645.00 | 7,611.00 |
| Mark F Rule | 1.20 | 910.00 | 1,092.00 |
| Richard Collura | 33.00 | 1,090.00 | 35,970.00 |
| Total Hours & Fees | 142.10 | | 104,994.00 |